

1

2 PBN-PVT projection modulates negative affective states in mice

3

4 Ya-Bing Zhu<sup>1,4</sup>, Yan Wang<sup>1,4</sup>, Xiao-Xiao Hua<sup>2,4</sup>, Ling Xu<sup>1</sup>, Ming-Zhe Liu<sup>3</sup>, Rui  
5 Zhang<sup>1</sup>, Peng-Fei Liu<sup>1</sup>, Jin-Bao Li<sup>1</sup>, Ling Zhang<sup>2,\*</sup>, Di Mu<sup>1,5,\*</sup>

6

7 <sup>1</sup>Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao  
8 Tong University School of Medicine, Shanghai, China, 201620, China

9 <sup>2</sup>The First Rehabilitation Hospital of Shanghai, Tongji University School of  
10 Medicine, Shanghai 200090, China

11 <sup>3</sup>Department of Respiratory, The First Affiliated Hospital of Guangzhou Medical  
12 University, Guangzhou 510120, China

13 <sup>4</sup>These authors contributed equally

14 <sup>5</sup>Lead Contact

15

16

17 \*Correspondence to:

18

19 Ling Zhang, Ph.D., The First Rehabilitation Hospital of Shanghai, Tongji  
20 University School of Medicine, Shanghai 200090, China; Email:  
21 lzhang0808@tongji.edu.cn.

22

23 Di Mu, Ph.D., Department of Anesthesiology, Shanghai General Hospital,  
24 Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China;  
25 Email: damonmu@163.com or dimu08207@ustc.edu

26

27 **Abstract**

28 Long-lasting negative affections dampen enthusiasm for life, and dealing with  
29 negative affective states is essential for individual survival. The parabrachial  
30 nucleus (PBN) and the thalamic paraventricular nucleus (PVT) are critical for  
31 modulating affective states in mice. However, the functional role of the  
32 PBN-PVT projection in modulating affective states remains elusive. Here, we  
33 show that the PBN neurons send dense projection fibers to the PVT and form  
34 direct excitatory synapses with the PVT neurons. Activation of the PBN-PVT  
35 projection or PVT-projecting PBN neurons induces robust anxiety-like,  
36 aversion-like, and fear-like behaviors without affecting nociceptive behaviors.  
37 Inhibition of the PBN-PVT projection or PVT-projecting PBN neurons reduces  
38 fear-like and aversion-like behaviors. Furthermore, the PVT neurons  
39 innervated by the PBN are activated by aversive stimulation, and activation of  
40 PBN-PVT projection enhances the neuronal activity of PVT neurons in  
41 response to the aversive stimulus. Activation of these downstream PVT  
42 neurons induces anxiety-like behavior behaviors. Thus, our study indicates  
43 that the PBN-PVT projection modulates negative affective states in mice.

44

45 **Keywords:** Parabrachial nucleus (PBN); thalamic paraventricular nucleus  
46 (PVT); affective states; anxiety; aversion.

47

48 **Introduction**

49 Threat and injury often induce defensive reactions, such as flight, freezing,  
50 hiding (*Öhman and Mineka, 2001*), and negative affective states, such as fear  
51 and anxiety (*Jimenez et al., 2018*). Such behavioral adaptations and  
52 psychological responses are essential for survival, and understanding the  
53 mechanisms is of fundamental interest. It is worth noting that the parabrachial  
54 nucleus (PBN) in the brainstem plays a critical role in encoding danger signals  
55 and promoting affective behavior states to limit harm in response to potential  
56 threats (*Campos et al., 2018*).

57       The PBN receives the majority of the ascending inputs from the spinal cord  
58 (*Todd, 2010*), and the PBN neurons respond robustly to nociception, food  
59 neophobia, hypercapnia, and threat for maintaining homeostasis under  
60 stressful circumstances (*Campos et al., 2018; Kaur et al., 2013*). The PBN  
61 relays this information (visceral malaise, taste, temperature, pain, itch) to brain  
62 areas, such as the hypothalamus, the central of the amygdala (CeA), thalamus,  
63 insular cortex (IC), and periaqueductal gray (PAG), to participate in diverse  
64 physiology process (*Chiang et al., 2019; Palmiter, 2018; Saper, 2016*). A  
65 recent study has found that the subpopulations of PBN have distinct projection  
66 patterns and functions (*Chiang et al., 2020*). The dorsal division PBN neurons  
67 projecting to the ventromedial hypothalamus (VMH) and PAG mediate  
68 escaping behaviors. In contrast, the external lateral division PBN neurons  
69 projecting to the bed nucleus of the stria terminalis (BNST) and the CeA  
70 mediate aversion and avoidance memory (*Chiang et al., 2020*). Optogenetic  
71 manipulation of specific outputs from PBN generates a specific function  
72 (*Bowen et al., 2020*). In the thalamus, the intralaminar thalamus nucleus (ILN)  
73 is the downstream target of PBN neurons that receive spinal cord inputs, and  
74 the ILN pathway participates in nociception processing (*Deng et al., 2020*).  
75 Besides the ILN nucleus, the thalamic paraventricular nucleus (PVT) is  
76 another primary target of the PBN nucleus in the thalamus (*Chiang et al.,*  
77 *2020*).

78       The PVT nucleus locates in the dorsal part of the midline thalamus (*Vertes*  
79 *et al., 2015*), and has been heavily implicated in a range of affective behaviors  
80 (*Hsu et al., 2014*). The functional roles of the PVT include diverse processes  
81 such as arousal (*Ren et al., 2018*), drug addiction (*Zhu et al., 2016*),  
82 reward-seeking (*Do-Monte et al., 2017; Engelke et al., 2021*), stress (*Beas et*  
83 *al., 2018; Gao et al., 2020*), associative learning and memory retrieval (*Penzo*  
84 *et al., 2015; Do-Monte et al., 2015; Zhu et al., 2018; Keyes et al., 2020*). The  
85 PVT receives a significant amount of inputs from the brainstem (locus  
86 coeruleus, PBN, PAG), hypothalamus, prefrontal cortical areas and projects to

87 the infralimbic cortex, nucleus accumbens (NAc), BNST, and CeA (*Kirouac,*  
88 *2015*). The convergent signals included the arousal from the hypothalamus  
89 (*Ren et al., 2018*), the emotional saliency from the prefrontal cortex  
90 (*Yamamuro et al., 2020*), and the stress responsivity from locus coeruleus (LC)  
91 (*Beas et al., 2018*) might help to promote the appropriate behavioral  
92 responses to environmental challenges. However, despite the substantial  
93 improvements in our understanding of the PVT nucleus's neurocircuitry, the  
94 functional role of the PBN-PVT projection remains mostly unknown.

95 In this study, we used virus tracing and electrophysiology to dissect the  
96 anatomical and functional connection between the PBN nucleus and the PVT  
97 nucleus. By using optogenetic and pharmacogenetic approaches, we then  
98 demonstrated that the PBN-PVT projection modulates negative affective  
99 states in mice.

100

## 101 **Results**

### 102 **Functional connectivity pattern of the PBN-PVT projection**

103 Previous studies have reported that the PVT could receive input from the PBN  
104 nucleus (*Chiang et al., 2020; Li and Kirouac, 2012*). The detailed morphology  
105 of the PBN-PVT projection and whether these two nuclei form direct functional  
106 synapses remain unknown. We first injected the AAV2/8-hSyn-ChR2-mCherry  
107 virus into the PBN and found that there were dense projection fibers in the PVT  
108 (*Figure 1A–C*). We employed the whole-cell patch-clamp recording to examine  
109 the synaptic connectivity between the PBN and the PVT. Precisely time-locked  
110 action potentials were induced by a train of brief laser pulses (5 Hz, 10 Hz, and  
111 20 Hz, *Figure 1G*). We found that optogenetic activation of the PBN projection  
112 fibers evoked excitatory postsynaptic currents (EPSCs) in 34 of 52 PVT  
113 neurons. The medial PVT showed higher connectivity (bregma -0.94 to -1.82  
114 mm, 27 of 37 cells, 72.97%) than anterior PVT (bregma -0.22 to -0.94 mm, 2 of  
115 6 cells, 33.33%) or posterior PVT (bregma -1.82 to -2.3 mm, 5 of 9 cells,  
116 55.56%, *Figure 1D–F*). The average amplitude of the light-evoked EPSCs was

117 103.4 ± 11.93 pA (*Figure 1H*). Moreover, the latency of EPSCs was 3.13 ± 0.29  
118 ms with a jitter of 0.16 ± 0.02 ms (*Figure 1I-J*), indicating monosynaptic  
119 connections between the PBN and the PVT nuclei. The EPSCs were sensitive  
120 to the Na<sup>+</sup> channel blocker tetrodotoxin (TTX, 1 μM) and were rescued by the  
121 K<sup>+</sup> channel blocker 4-aminopyridine (4-AP, 100 μM). The EPSCs were further  
122 blocked by the AMPA receptor antagonist NBQX (10 μM), confirming the  
123 monosynaptic glutamatergic innervation of the PVT neurons by the PBN  
124 neurons (*Figure 1K-L*). In addition, we also observed there were light-evoked  
125 inhibitory postsynaptic currents (IPSCs) in only 2 of 52 PVT neurons (less than  
126 30 pA).

127 Next, we injected the retroAAV2/2-hSyn-Cre virus into the PVT nucleus on  
128 *Rosa26-tdTomato* mice which could retrogradely label projection neurons in  
129 the PBN (*Figure 1M-P*). We found that tdTomato<sup>+</sup> neurons were bilaterally  
130 located in the lateral PBN (55 ± 5.82 neurons, *n* = 4 mice) and rarely in the  
131 medial PBN (7.75 ± 1.03 neurons, *Figure 1O-Q*). These results indicate that  
132 bilateral PBN project to the PVT. We then performed tdTomato staining with  
133 *type 2 vesicular glutamate transporter (Vglut2)* mRNA in situ hybridization and  
134 found that about 94.4% of tdTomato neurons express *Vglut2 mRNA* (*Figure*  
135 *1R-U*). These results indicate that the majority of PVT-projecting PBN neurons  
136 are glutamatergic. We also examined several markers for subpopulations of  
137 PBN neurons, including tachykinin 1 receptor (*Tacr1*), tachykinin 1 (*Tac1*),  
138 prodynorphin (*Pdyn*), calcitonin gene-related peptide (*CGRP*). And we found  
139 that tdTomato neurons were only partially co-labeled with *Tacr1*, *Tac1*, or *Pdyn*  
140 mRNA, but not with *CGRP* (*Figure 1-figure supplement 1*).

141 Then, we used the *Vglut2-ires-Cre* mice combined with the  
142 AAV2/8-EF1a-DIO-EGFP virus to specifically label the glutamatergic neurons  
143 of the PBN nucleus (*Figure 1-figure supplement 2A*). Robust expression of  
144 AAV2/8-EF1a-DIO-EGFP was found in both the lateral and medial PBN nuclei  
145 (*Figure 1-figure supplement 2B-D*). It is worth noting that the density of EGFP<sup>+</sup>  
146 fibers was higher in the middle and posterior PVT (*Figure 1-figure supplement*

147 2E–H), considering that the notion of the posterior PVT being a particularly  
148 aversive region of the PVT (Gao *et al.*, 2020). We also examined the collateral  
149 projections from PVT-projecting PBN neurons (Figure 1–figure supplement 3).  
150 The collateral projections were also found in the BNST, lateral hypothalamus  
151 (LH), paraventricular nucleus of the hypothalamus (PVN), PAG, but not CeA or  
152 VMH.

153

### 154 **Optogenetic activation of PBN-PVT projection induces anxiety-like** 155 **behaviors and aversion-like behaviors**

156 We injected the AAV2/9-EF1a-DIO-ChR2-mCherry virus or  
157 AAV2/9-EF1a-DIO-mCherry virus into the bilateral PBN of *VgluT2-ires-Cre*  
158 mice and implanted optic fibers above the PVT to activate the PBN-PVT  
159 projection selectively (Figure 2A). Four weeks after surgery, we found robust  
160 expression of ChR2-mCherry (Figure 2B–C, Figure 2–figure supplement 1A)  
161 or mCherry (Figure 2–figure supplement 1C) in bilateral PBN neurons and the  
162 axon terminals in the PVT (Figure 2D, Figure 2–figure supplement 1B, Figure  
163 2–figure supplement 1D).

164 We performed a 15 minutes optogenetic manipulation open field test (OFT,  
165 0–5 minutes laser OFF, 5–10 minutes laser ON, 10–15 minutes laser OFF,  
166 Figure 2E). Optogenetic activation (473 nm, 20 Hz, 5 mW, 5ms) of the  
167 efferents from the PBN to the PVT elicited instant running behavior along the  
168 chamber wall with a significantly increased velocity in ChR2 group mice  
169 (Figure 2F–H, Figure 2–video 1). The ChR2 injected mice rarely entered into  
170 the center area of the chamber, represented as a decrease in center time than  
171 that of the control group (Figure 2I). It is worth noting that the velocity returned  
172 to normal once the laser was off, but the time spent in the center was still lower  
173 than the control group in the 5 minutes after stimulation. These results  
174 indicated that the anxiety could last for at least several minutes after acute  
175 activation. Although the speed increased during the laser ON period, the  
176 unmoving time of the ChR2 mice during the laser ON period was also

177 increased (*Figure 2–figure supplement 2A*). Therefore, the distance during the  
178 laser ON period and the total distance in 15 minutes were not changed (*Figure*  
179 *2–figure supplement 2B*).

180 To dissect a more detailed profile of the behaviors in the OFT, we further  
181 divided the laser ON period (5–10 minutes) into 5 one-minute periods and  
182 analyzed the velocity, unmoving time, center time, distance, and jumping  
183 (*Figure 2–figure supplement 2C–G*). We found that the velocity and unmoving  
184 time were increased, and the center time was decreased in the ChR2 mice  
185 during most periods (*Figure 2–figure supplement 2C–E*). Furthermore, we  
186 observed that the distance and jumping behaviors were increased mainly in  
187 the first one-minute period in ChR2 mice (*Figure 2–figure supplement 2F–G*).  
188 This detailed analysis indicates that optogenetic activation induces brief and  
189 robust running, jumping behaviors, and persistent anxiety-like behaviors, such  
190 as unmoving and less time spent in the center.

191 Besides anxiety, another critical component of negative affective states is  
192 aversion. Therefore, we used the real-time placed aversion test (RTPA) to  
193 explore the function of optogenetic activation of the PBN-PVT projection  
194 (*Figure 2J*). We found that the ChR2 mice spent less time in the laser-paired  
195 chamber, and the aversion disappeared when the laser was off (*Figure 2K–M,*  
196 *Figure 2–video 2*). We also used a prolonged conditioning protocol that mimics  
197 drug-induced conditioned place aversion (*Figure 2–figure supplement 2H*). We  
198 found that the ChR2 mice did not display aversion in the post-conditioning test  
199 (*Figure 2–figure supplement 2I*). These results indicate that activation of the  
200 PBN-PVT projection is sufficient to induce aversion but could not enable  
201 associative aversive memory formation.

202 To further confirm this instant aversion phenomenon, we subjected mice to  
203 the cue-dependent optogenetic conditioning test (*Figure 2N*). A 30 seconds  
204 auditory conditioning stimulus (CS) co-terminated with 30 seconds of  
205 synchronous optogenetic activation of the PBN-PVT projection (laser stimulus,  
206 LS) in this test. The ChR2 expressing mice generated significant freezing



207 behavior during 6 CS-LS pairings (*Figure 2O*). However, the freezing behavior  
208 to the same context or to the auditory cue in a novel context was disappeared  
209 on the second day (*Figure 2P–Q*). These results demonstrate that optogenetic  
210 activation of the PBN-PVT projection induces instant aversion and freezing but  
211 does not drive associative fear memory formation.

212

### 213 **Pharmacogenetic activation of the PVT-projecting PBN neurons induces** 214 **anxiety-like behaviors and freezing behaviors**

215 We also used pharmacogenetic manipulation and retrograde tracing to confirm  
216 the effects of activating the PVT-projecting PBN neurons. We first injected the  
217 retroAAV2/2-hSyn-Cre virus into the PVT, and the  
218 AAV2/9-hSyn-DIO-hM3Dq-mCherry virus or control virus into bilateral PBN to  
219 specifically transduce the PVT-projecting PBN neurons with a designer  
220 receptor exclusively activated by designer drugs (DREADDs, *Figure 3A*)  
221 (*Armbruster et al., 2007*). The PVT-projecting PBN neurons could be activated  
222 by intraperitoneal injection of clozapine N-oxide dihydrochloride (CNO, *Figure*  
223 *3B–D*). The region of the virus expression in the PBN nucleus is shown in  
224 *Figure 3–figure supplement 1*. Consistent with the optogenetic activation  
225 results, the hM3Dq mice spent less time in the center, had more unmoving  
226 time, and traveled fewer distances than the mCherry mice in the OFT (*Figure*  
227 *3E–I*). At the same time, the velocities were not significantly different (*Figure*  
228 *3J*). We also found that activation of the PVT-projecting PBN neurons did not  
229 affect motor ability in the rotarod test (*Figure 3–figure supplement 2G*).  
230 Besides, the hM3Dq mice showed decreased exploration time of open  
231 quadrants in the EZM (*Figure 3K–L*), further suggesting that activation of  
232 PVT-projecting PBN neurons could induce anxiety-like behaviors.

233 We further evaluated freezing behaviors in the fear conditioning chamber  
234 and found that the hM3Dq mice displayed more freezing behaviors after  
235 injection of CNO than control mice (*Figure 3M–N*). Although activation of  
236 PVT-projecting PBN neurons induced significant anxiety-like behavior, it did



237 not affect the depressive-like behaviors evaluated by the tail suspension test  
238 (TST, *Figure 3–figure supplement 2A*) and the forced swimming test (FST,  
239 *Figure 3–figure supplement 2B*). Previous studies have revealed that the PBN  
240 receives direct projections from the spinal cord and plays a vital role in pain  
241 processing (*Deng et al., 2020; Sun et al., 2020*). We then assessed whether  
242 pharmacogenetic activation of the PVT-projecting PBN neurons affects the  
243 nociceptive behaviors. By performing the von Frey test and Hargreaves test,  
244 we found that the basal nociceptive thresholds were not affected after  
245 pharmacogenetic activation of PVT-projecting PBN neurons (*Figure 3–figure*  
246 *supplement 2C–D*). Given that the distinct mechanisms between the reflexive  
247 and coping responses induced by nociceptive stimulation (*Huang et al., 2019*),  
248 we injected formalin into the paw to induce inflammatory pain. We found that  
249 activation of the PVT-projecting PBN neurons did not affect the  
250 formalin-evoked licking behaviors (*Figure 3–figure supplement 2E–F*). These  
251 results indicate that the PBN-PVT projection might not participate in the pain  
252 signal processing.

253

### 254 **Inhibition of the PBN-PVT projection reduces the 2-MT-induced aversive** 255 **behaviors and footshock-induced fear behaviors**

256 The activation manipulation results prompted us to investigate whether  
257 inhibition of the PBN-PVT projection could modulate the negative affective  
258 states. We first injected the AAV2/9-EF1a-DIO-NpHR3.0-EYFP virus or the  
259 AAV2/8-EF1a-DIO-EGFP virus into the PBN and implanted the optic fibers into  
260 the PVT of *VgluT2-ires-Cre* mice (*Figure 4A–C, Figure 4–figure supplement 1*).  
261 We used 2-methyl-2-thiazoline (2-MT), a widely-used odorant molecule that  
262 could generate innate fear-like freezing responses in rodents (*Isosaka et al.,*  
263 *2015*), to induce the fear-like state. We found that 589 nm laser-induced  
264 inhibition of the PBN-PVT projection reduced the aversion caused by the 2-MT  
265 (*Figure 4D–F*) and increased the moving duration (*Figure 4G*). We also  
266 observed that inhibition of the PBN-PVT projection increased the time in the

267 2-MT zone in the OFT (*Figure 4H–I*). Besides the 2-MT, footshock is another  
268 paradigm that induces robust freezing behaviors. We found that constant  
269 inhibition of the PBN-PVT projection reduced the footshock-induced freezing  
270 behaviors (*Figure 4J–K*).

271 We also examined whether inhibition of the PBN-PVT projection affects  
272 aversive memory acquisition or retrieval (*Figure 4–figure supplement 2A*). We  
273 briefly suppressed the activity of the PBN-PVT projection during footshock  
274 stimulation and found that freezing levels were not changed (*Figure 4–figure*  
275 *supplement 2B*). We further compared the freezing levels in contextual and  
276 cue tests without or with laser and found that aversive memory retrieval was  
277 not affected either (*Figure 4–figure supplement 2C–D*). In addition, we  
278 performed optogenetic inhibition of the PVT-projecting PBN neurons and  
279 observed similar phenomena (*Figure 4–figure supplement 3*).

280

### 281 **PBN input shapes PVT neuronal responses to aversive stimulation**

282 By using *in vivo* fiber photometry, we found that the calcium signals of the PVT  
283 neurons were increased after aversive stimuli, such as footshock and air puff  
284 (*Figure 5–figure supplement 1*), indicating that the calcium signal of the PVT  
285 neurons is increased in response to aversive stimuli. Besides, we injected the  
286 AAV2/1-hSyn-Cre virus, which could anterogradely label the downstream  
287 neurons (*Zingg et al., 2017*), into the PBN of *Rosa26-tdTomato* mice (*Figure*  
288 *5A*). The distribution pattern of tdTomato<sup>+</sup> neurons in PVT (hereafter referred to  
289 as PVT<sub>PBN</sub> neurons) was shown in *Figure 5B–D*. We used Fos as a marker to  
290 assess the activity change in 2-MT treated mice and footshock treated mice.  
291 The percentage of Fos<sup>+</sup>tdTomato<sup>+</sup> neurons/tdTomato<sup>+</sup> neurons in the PVT was  
292 significantly increased in the aversive stimuli-treated mice than that of control  
293 mice (*Figure 5E–H*), confirming that the PVT<sub>PBN</sub> neurons could be activated by  
294 aversive stimuli.

295 The next question is whether the PBN-PVT projection modulates the  
296 neuronal activity of the PVT neurons in response to aversive stimuli. We first

297 injected the AAV2/9-EF1a-DIO-ChR2-mCherry virus into the PBN and  
298 performed a dual Fos staining (*Seike et al., 2020*), detecting *fos* mRNA and  
299 Fos protein induced by two episodes of stimulation (*Figure 6–figure*  
300 *supplement 1A*). We found that there was a broad overlap between  
301 optogenetic stimulation-activated neurons (expressing the Fos protein) and  
302 footshock-activated neurons (expressing the *fos* mRNA) (*Figure 6–figure*  
303 *supplement 1B–E*). Then we injected the AAV2/9-EF1a-DIO-ChR2-mCherry  
304 virus into the PBN and implanted the optoelectrode into the PVT of  
305 *Vglut2-ires-Cre* mice (*Figure 6A*). We first recorded the spiking signals in  
306 response to 10 sweeps of 2 s laser pulse trains (20 Hz, 5 mW, 5 ms). Then we  
307 recorded the spiking signals in response to 20 sweeps of 2 s footshock (0.5  
308 mA) without laser in odd number sweeps or with laser in even number sweeps  
309 (*Figure 6A*). We found that laser or footshock (without laser) increased firing  
310 rates in 22 or 28 of 40 units (*Figure 6B–C*). And there was also a broad overlap  
311 between laser-activated and footshock-activated units (*Figure 6D*). It was  
312 consistent with the dual Fos staining result, suggesting that PVT<sub>PBN</sub> neurons  
313 are activated by aversive stimulation. Next, we analyzed the firing rates of PVT  
314 neurons in footshock with laser sweeps and footshock without laser sweeps  
315 (*Figure 6E–G*). We found that the footshock stimulus with laser activated 30 of  
316 40 units (*Figure 6H*) and increased the overall firing rates of neurons  
317 compared with the footshock without laser result (*Figure 6I*). These results  
318 indicate that activation of the PBN-PVT projection could enhance the PVT  
319 neuronal responses to aversive stimulation.

320

### 321 **Pharmacogenetic activation of the PVT<sub>PBN</sub> neurons induces anxiety-like** 322 **behaviors**

323 To further investigate the specific role of PVT<sub>PBN</sub> neurons in modulating  
324 negative affective states, we injected the AAV2/1-hSyn-Cre virus into the  
325 bilateral PBN and injected the AAV2/9-hSyn-DIO-hM3Dq-mCherry virus or  
326 control virus into the PVT to activate the PVT<sub>PBN</sub> neurons (*Figure 7A*). The

327 majority of the PVT<sub>PBN</sub> neurons could be activated by CNO in the hM3Dq  
328 expressing mice but not the control mice (*Figure 7B–D*). We found that  
329 pharmacogenetic activation of the PVT<sub>PBN</sub> neurons reduced the center time  
330 (*Figure 7E–F*). Similarly, the time spent in open quadrants was decreased in  
331 the EZM of hM3Dq expressing mice (*Figure 7G–H*). And the unmoving time in  
332 the EZM test had an increased tendency in hM3Dq expressing mice (*Figure 7I*).  
333 We did not observe obvious nociception-related behaviors, such as forelimb  
334 wiping, hindlimb flinching, licking, or biting during the experiments. These  
335 results indicate that pharmacogenetic activation of PVT<sub>PBN</sub> neurons induces  
336 anxiety-like behaviors.

337 Furthermore, we examined the anatomic distribution of terminals of  
338 PVT<sub>PBN</sub> neurons. We labeled the PVT<sub>PBN</sub> neurons in WT mice by injecting the  
339 AAV2/1-hSyn-Cre virus into the PBN and AAV2/8-EF1a-DIO-EGFP virus into  
340 the PVT (*Figure 7-figure supplement 1A–B*). We found that the PVT<sub>PBN</sub>  
341 neurons sent projections to several brain areas, in particular the nucleus  
342 accumbens core (NAc), BNST, and CeA (*Figure 7-figure supplement 1B–H*),  
343 which was similar to the early tracing research of PVT efferent projections  
344 (*Kirouac, 2015*).

345

## 346 **Discussion**

347 In this study, we employed viral tracing and electrophysiology to confirm the  
348 monosynaptic excitatory connectivity between the PBN and the PVT.  
349 Optogenetic or pharmacogenetic activation of the PBN-PVT projection or the  
350 PVT-projecting PBN neurons induced anxiety-like, aversion-like, and fear-like  
351 behaviors. Optogenetic inhibition of the PBN-PVT projection or the  
352 PVT-projecting PBN neurons could partially reduce 2-MT induced aversive  
353 behaviors as well as footshock-induced freezing behaviors. The activity of  
354 PVT<sub>PBN</sub> neurons was increased in several aversive stimuli and could be further  
355 increased by activation of PBN-PVT projection. Besides, activation of PVT<sub>PBN</sub>  
356 neurons induced anxiety-like behaviors. Taken together, our results reveal the

357 functional role of the PBN-PVT projection in modulating negative affective  
358 states in mice.

359

### 360 **PBN efferents and PBN-PVT monosynaptic excitatory projection**

361 The PBN is a critical hub receiving sensory information from the spinal  
362 cord (*Todd, 2010*). The widespread distribution of PBN efferents contributes to  
363 different aspects of behavioral and physiological responses. Previous studies  
364 showed that the CGRP-expressing neurons in the PBN project to the CeA  
365 contribute to the affective dimension of pain. In contrast, non-CGRP neurons  
366 may transmit sensory pain information (*Han et al., 2015*). The projections from  
367 the PBN to the VMH or PAG are involved in producing escape behaviors to  
368 avoid injury, while the projections from the PBN to the BNST or CeA participate  
369 in facilitating aversive memory (*Chiang et al., 2020*). The PBN neurons, which  
370 receive projections from the spinal cord, form strong functional synaptic  
371 connections with the ILN neurons but not the CeA neurons to process the  
372 nociceptive signals (*Deng et al., 2020*). The PVT nucleus located in the middle  
373 line of the brain is an important area that participates in affective states  
374 processing (*Kirouac, 2015*). Although recent research has reported that the  
375 projecting fibers from PBN were found in the PVT (*Chiang et al., 2020*),  
376 remarkably little is known about the connectivity information and function of the  
377 PBN-PVT projection.

378 Since we injected the constitutively expressed ChR2 virus into the PBN,  
379 few neurons in the LC (which is medial to the PBN) might be infected. The LC  
380 neurons express the Vglut1 and also project to the PVT (*Beas et al., 2018*).  
381 Although the PBN-PVT projection comprises the major portion of the  
382 projections, there is still potential contamination from the LC-PVT projections.  
383 We also observed a small portion of inhibitory connections between the PBN  
384 and the PVT. It is consistent with the previous study showing GABAergic  
385 neurons in the PBN also send sparse projections to the PVT (*Chiang et al.,*  
386 *2020*). Further in situ hybridization results confirmed that the PVT-projecting

387 PBN neurons are mainly glutamatergic neurons expressing *Vglut2* mRNA.  
388 These results suggest that the majority of the PBN-PVT projection appeared to  
389 be excitatory.

390 We also found that the density of PBN glutamatergic is higher in the middle  
391 and posterior PVT (pPVT). These results are consistent with the various  
392 studies supporting that pPVT is a particularly aversive region of the PVT (*Gao*  
393 *et al.*, 2020; *Beas et al.*, 2018; *Barson et al.*, 2020).

394

### 395 **PBN-PVT projection modulates negative affective states**

396 We found that activation of PBN-PVT projection or the PVT-projecting PBN  
397 neurons induced anxiety-like behaviors and fear-like behaviors in the OFT and  
398 EZM. We observed that mice displayed robust running and jumping behaviors  
399 mainly in the first minute in optogenetic manipulation, and these phenomena  
400 were not observed in the pharmacogenetic experiment. These might be  
401 caused by an instantly increased activity of PBN-PVT projection induced by  
402 optogenetic manipulation. Mice might display “fight or flight” during sudden  
403 affective state transitions. And the pharmacogenetic approach takes several  
404 minutes to gradually enhance neural activity, and the affective state changes in  
405 a relatively mild way. We also observed that the anxiety-like behaviors in the  
406 OFT still existed several minutes after optogenetic activation of the PBN-PVT  
407 projection. However, in the RTPA test, the aversion appeared when the laser  
408 was on and disappeared when the laser was off, indicating the aversion was  
409 transient and could not be translated to associative learning. It was further  
410 confirmed by the prolonged condition place aversion test and cue-dependent  
411 optogenetic conditioning test. These results suggest that activation of the  
412 PBN-PVT induces instant negative affective states but does not drive  
413 associative fear memory formation.

414 Selectively optogenetic inhibition of PBN-PVT projection or PVT-projecting  
415 PBN neurons could reduce aversion-like and fear-like behaviors. To better  
416 examine the behavioral changes, we performed 10 minutes test in 2-MT and

417 footshock experiments. So we used a relatively long-term protocol in  
418 optogenetic inhibition experiments (10 minutes constant laser). Such long-term  
419 inhibition protocols were used in other studies (*Zhou et al., 2019; Sun et al.,*  
420 2020). We also performed the classical fear conditioning test and found that  
421 inhibition of the PBN-PVT projection did not affect associative fear memory  
422 formation or retrieval, suggesting that the PBN-PVT projection mainly  
423 promotes aversion but does not facilitate negative association.

424 Our calcium imaging and Fos staining results indicated PVT neurons were  
425 activated after exposure to aversive stimuli, consistent with a previous study  
426 (*Zhu et al., 2018*). The dual Fos staining experiment and optoelectrode  
427 experiments confirmed a broad overlap between laser-activated and  
428 footshock-activated neurons. Further analysis showed that activation of the  
429 PBN-PVT projection enhanced the overall firing rates of PVT neurons in  
430 response to footshock. These results suggest that the activation of the  
431 PBN-PVT could enhance the neuronal activity in response to aversive  
432 stimulation.

433 The activation of PBN innervated PVT neurons induced anxiety-like  
434 behaviors, suggesting the PVT<sub>PBN</sub> neurons are involved in modulating  
435 negative affective states. Previous studies have reported that activation of the  
436 PBN-CeA pathway is sufficient to drive a series of negative affective states  
437 behaviors (*Bowen et al., 2020; Cai et al., 2018; Han et al., 2015*), enable  
438 associative learning, and generate aversive memory (*Chiang et al., 2020*).  
439 Distinct from the PBN-CeA projection, we found that activation of the PBN-PVT  
440 projection only induced transient aversion-related behaviors, and inhibition of  
441 the PBN-PVT projection did not affect fear memory acquisition or retrieval. A  
442 study reported that only a few Fluoro-gold (FG)/tetramethylrhodamine-dextran  
443 (TMR) double-labeled neurons were sparsely distributed in the PBN of the  
444 mice injected with FG into the PVT and TMR into the CeA (*Liang et al., 2016*).  
445 Our results also showed few collateral projecting fibers in the CeA or VMH  
446 from the PVT-projecting PBN neurons. These results suggested that the



447 PBN-PVT pathway and the PBN-CeA pathway are two parallel pathways  
448 originating from distinct efferent neurons within the PBN to perform distinct  
449 functions. However, we also observed collateral projection fibers in BNST, LH,  
450 PVN, PAG, but not CEA or VMH. The PBN-PAG projection is suggested to  
451 mediate escaping behaviors (*Chiang et al., 2020*). The possibility of antidromic  
452 effects following photoactivation of PBN terminals in PVT should be reminded.

453 The tracing results showed the PVT<sub>PBN</sub> neurons projected to multiple brain  
454 areas, particularly the NAc, BNST, and CeA. The BNST and CeA have been  
455 previously implicated in negative affective behaviors (*Jennings et al., 2013*;  
456 *Tye et al., 2011*). Previous studies showed that the activation of the PVT-CeA  
457 projections induces place aversion, and the effect persists on the next day in  
458 the absence of photostimulation (*Do Monte et al., 2017*). Similarly, long-term  
459 depression (LTD)-like the stimulation of PVT-CeA projections or inhibition of  
460 the same circuit induces a persistent attenuation of fear responses (*Chen and*  
461 *Bi., 2019*; *Do Monte et al., 2015*; *Penzo et al., 2015*). These results revealed a  
462 critical role of the PVT-CeA projection in aversive memory formation. In our  
463 study, we found that PBN-PVT is not crucial for aversive memory formation.  
464 The possible reason might be that manipulation of the PVT-CeA induces direct  
465 excitatory inputs to the CeA, and the inputs are strong enough for aversive  
466 memory formation. However, activation of the PBN-PVT projection might not  
467 induce enough excitatory inputs to the CeA via the disynaptic connection.

468 A study also found that PVT mediates descending pain facilitation  
469 underlying persistent pain conditions via the PVT-CeA-PAG circuit (*Liang et al.,*  
470 *2020*). Different downstream pathways of PVT<sub>PBN</sub> neurons might have different  
471 functions and deciphering the circuit mechanisms needs further examination.

472

### 473 **The potential role of PBN-PVT projection in depression and pain**

474 It is worth noting that although the pharmacogenetic activation of the  
475 PVT-projecting PBN neurons induced anxiety-like behaviors and fear-like  
476 behaviors in the hM3Dq group mice, no depression-like symptoms were

477 observed in TST and FST. On the other side, chronic pain models, such as the  
478 partial sciatic nerve ligation model, the spared nerve injury model, and  
479 complete Freund's adjuvant model, generally induce anxiety and depression at  
480 least 3–4 weeks after the surgery in mice (*Dimitrov et al., 2014; Zhou et al.,*  
481 *2019*). Our study collected the behavioral data 30 minutes after a single dose  
482 of CNO injection. Different behavioral tests were performed at least three days  
483 apart to eliminate the residual CNO effects. We hypothesized that  
484 depression-like behaviors might be observed if we repeatedly activate the  
485 PBN-PVT projection for weeks. However, whether the PBN-PVT is involved in  
486 depression is still unknown.

487 A recent study revealed that the PBN neurons convey nociception  
488 information from the spinal cord to the ILN, which is relatively closed to the  
489 PVT (*Deng et al., 2020*). In our results, we carefully checked the virus  
490 expression and optic fiber locations of mice. We found that pharmacogenetic  
491 activation of PVT-projecting PBN neurons did not affect the basal nociceptive  
492 thresholds or formalin-induced licking behaviors. Moreover, no obvious  
493 nociception-related behaviors (such as forelimb wiping, hindlimb flinching,  
494 licking, or biting) were found through specific manipulation of the PBN  
495 innervated PVT neurons, which suggests that the PBN-PVT projection might  
496 be not involved in nociceptive information processing.

497 In summary, we identified the functional role of the PBN-PVT projection in  
498 modulating negative affective states. Our study paves the way for further  
499 deciphering the distinct roles of the PBN neural circuit in affective behaviors.

500

## 501 **Acknowledgements**

502 We thank Dr. Hua-Tai Xu for providing *Rosa26-tdTomato* mice. We thank Dr.  
503 Yan-Gang Sun for providing *Vglut2-ires-Cre* mice. We thank all the lab  
504 members of D.M. for their helpful discussion. This work was supported by the  
505 National Natural Science Foundation of China (No. 31900717, 31571086), the  
506 Shanghai Sailing Program (19YF1438700 to D.M.), the Young Elite Scientists

507 Sponsorship Program of China Association for Science and Technology  
508 (2019QNRC001 To D.M.), and the Starting Research Fund from the Shanghai  
509 General Hospital.

510

#### 511 **Author contributions**

512 Y.B.Z. performed the virus injection experiments and behavioral experiments.  
513 Y.W. performed the dual Fos staining experiments. X.X.H. and Y.W. performed  
514 the optoelectrode experiments. R.Z. performed the electrophysiological  
515 experiments. Y.B.Z., Y.W., M.Z.L., and P.F.L. performed the histological  
516 experiments. J.B.L., L.Z., and D.M. designed the experiments. Y.B.Z. and D.M.  
517 wrote the manuscript.

518

#### 519 **Materials and methods**

##### 520 **Animals**

521 Male C57Bl/6J wild-type mice, *Rosa26-tdTomato* mice (Jax Stock No: 007909,  
522 gifted from Dr. Hua-Tai Xu, Institutes of Neuroscience, Chinese Academic of  
523 Sciences), *Vglut2-ires-Cre* mice (Jax Stock No: 016963, gifted from Dr.  
524 Yan-Gang Sun, Institutes of Neuroscience, Chinese Academic of Sciences)  
525 were used. Animals were housed in standard laboratory cages in a  
526 temperature (23-25°C)-controlled vivarium with a 12:12 light/dark cycle, free to  
527 food and water. For tracing and behavioral experiments, the mice were  
528 injected with the virus at 7–8 weeks old and performed the behavioral tests at  
529 11–12 weeks old. For the electrophysiological experiments, the mice were  
530 injected with the virus at 4–6 weeks old to accomplish the electrophysiological  
531 experiments at 7–9 weeks old. For *in vivo* fiber photometry and optoelectrode  
532 experiments, the mice were injected with the virus at 7–8 weeks old to  
533 accomplish the experiments at 10–11 weeks old. All animal experiment  
534 procedures were approved by the Animal Care and Use Committee of  
535 Shanghai General Hospital (2019AW008).

##### 536 **Stereotaxic surgery**

537 Mice were anesthetized by vaporized sevoflurane (induction, 3%; maintenance,  
538 1.5%) and head-fixed in a mouse stereotaxic apparatus (RWD Life Science  
539 Co.).

540 For electrophysiological experiments, the AAV2/8-hSyn-ChR2-mCherry  
541 virus (300 nl,  $4 \times 10^{12}$  v.g./ml, AG26976, Obio Technology) was injected into  
542 the PBN nucleus of WT mice in the stereotaxic coordinate: anteroposterior (AP)  
543  $-5.2$  mm, mediolateral (ML)  $+1.3$  mm, and dorsoventral (DV)  $-3.4$  mm.

544 For tracing studies, the AAV2/8-EF1a-DIO-EGFP virus (300 nl, S0270,  
545 Taitool Bioscience) was injected into the PBN (mentioned above) of  
546 *VgluT2-ires-Cre* mice.

547 For the retrovirus injection surgery, the retrograde transport Cre  
548 recombinase retroAAV2/2-hSyn-Cre virus (150 nl,  $4 \times 10^{12}$  v.g./ml,  
549 S0278-2RP-H20, Taitool Bioscience) was injected in the *Rosa26-tdTomato*  
550 mice at two locations of PVT respectively: (1) AP  $-1.22$  mm, ML 0 mm, DV  
551  $-2.9$  mm; (2) AP  $-1.46$  mm, ML 0 mm, DV  $-2.9$  mm.

552 For optogenetic activation of PVT-projecting PBN fibers, the  
553 AAV2/9-EF1a-DIO-ChR2-mCherry virus (300 nl,  $4 \times 10^{12}$  v.g./ml, S0170,  
554 Taitool Bioscience) or the AAV2/9-EF1a-DIO-mCherry virus (300 nl,  $4 \times 10^{12}$   
555 v.g./ml, AG20299, Obio Technology) were bilaterally injected into the PBN  
556 (mentioned above) of *VgluT2-ires-Cre* mice, and a 200  $\mu$ m diameter optic fiber  
557 was implanted over the PVT (AP  $-1.46$  mm, ML 0 mm, DV  $-2.9$  mm) with a 20°  
558 angle towards the midline.

559 For the pharmacogenetic activation of PVT-projecting PBN neurons, the  
560 retroAAV2/2-hSyn-Cre virus (150 nl,  $4 \times 10^{12}$  v.g./ml, S0278-2RP-H20, Taitool  
561 Bioscience) was injected into the PVT (AP  $-1.46$  mm, ML 0 mm, DV  $-2.9$  mm),  
562 the AAV2/9-hSyn-DIO-hM3Dq-mCherry virus (300 nl,  $4 \times 10^{12}$  v.g./ml, PT-0019,  
563 BrainVTA) or the control AAV2/9-EF1a-DIO-mCherry virus were bilateral  
564 injected into the PBN (mentioned above) of the WT mice.

565 For optogenetic inhibition of PVT-projecting PBN fibers,  
566 AAV2/9-EF1a-DIO-NpHR3.0-EYFP virus (300 nl,  $4 \times 10^{12}$  v.g./ml, AG26966,

567 Obio Technology) or the AAV2/8-EF1a-DIO-EGFP virus were bilaterally  
568 injected into the PBN (mentioned above) of *VgluT2-ires-Cre* mice, and a 200  
569  $\mu\text{m}$  diameter optic fiber was implanted over the PVT (AP  $-1.46$  mm, ML 0 mm,  
570 DV  $-2.9$  mm) with a  $20^\circ$  angle towards the midline.

571 For optogenetic inhibition of PVT-projecting PBN neurons,  
572 retroAAV2/2-hSyn-Cre was injected into the PVT (AP  $-1.46$  mm, ML 0 mm, DV  
573  $-2.9$  mm), AAV2/9-EF1a-DIO-NpHR3.0-EYFP virus (300 nl,  $4 \times 10^{12}$  v.g./ml,  
574 AG26966, Obio Technology) or the AAV2/8-EF1a-DIO-EGFP virus was  
575 injected into the PBN of WT mice, the left optic fiber was implanted over the  
576 PBN vertically and the right one were placed over the PBN with a  $20^\circ$  angle  
577 towards the midline.

578 For *in vivo* fiber photometry experiments, the AAV2/8-hSyn-GCaMP6s  
579 virus (200 nl,  $4 \times 10^{12}$  v.g./ml, S0225-8, Taitool Bioscience) was injected into  
580 the PVT nucleus (AP  $-1.46$  mm, ML 0 mm, DV  $-2.90$  mm) of the WT mice, the  
581 optic fiber was implanted above the PVT with a  $20^\circ$  angle towards the midline.

582 For optoelectrode experiments, the AAV2/9-EF1a-DIO-ChR2-mCherry  
583 virus (300 nl,  $4 \times 10^{12}$  v.g./ml, AAV2/9-S0170, Taitool Bioscience) were  
584 bilaterally injected into the PBN (mentioned above) of *VgluT2-ires-Cre* mice.  
585 Three weeks later, the homemade optoelectrode was implanted into the PVT  
586 nucleus (AP  $-1.46$  mm, ML 0 mm, DV  $-2.90$  mm).

587 For pharmacogenetic activation of PVT<sub>PBN</sub> neurons, the AAV2/1-hSyn-Cre  
588 virus (300 nl,  $1.5 \times 10^{13}$  v.g./ml, S0278-1-H50, Taitool Bioscience) was  
589 bilaterally injected into the PBN nucleus, the  
590 AAV2/9-hSyn-DIO-hM3Dq-mCherry virus or the control  
591 AAV2/9-EF1a-DIO-mCherry virus was injected into the PVT (AP  $-1.46$  mm, ML  
592 0 mm, DV  $-2.9$  mm) of the WT mice.

593 The virus was infused through a glass pipette ( $10\text{--}20$   $\mu\text{m}$  in diameter at the  
594 tip) at the rate of  $50\text{--}100$  nl/minute. The injection pipette was left in place for  
595 additional 8 minutes. After the surgeries, the skin was closed by the sutures,  
596 and the optic fiber was secured through the dental acrylic. Generally, tracing,

597 electrophysiological or behavioral experiments were performed at least three  
598 weeks later. After experiments, histological analysis was used to verify the  
599 location of viral transduction and the optic fiber. The mice without correct  
600 transduction of virus or correct site of optic fiber were excluded for analysis.

### 601 **Histology**

602 Animals were deeply anesthetized with vaporized sevoflurane and  
603 transcardially perfused with 20 ml saline, followed by 20 ml paraformaldehyde  
604 (PFA, 4% in PBS). Brains were extracted and soaked in 4% PFA at 4°C for a  
605 minimum of 4 hours and subsequently cryoprotected by transferring to a 30%  
606 sucrose solution (4°C, dissolved in PBS) until brains were saturated (for 36–48  
607 hours). Coronal brain sections (40 µm) were cut using a freezing microtome  
608 (CM1950, Leica). The slices were collected and stored in PBS at 4°C until  
609 immunohistochemical processing. Nuclei were stained with DAPI (Beyotime,  
610 1:10000) and washed three times with PBS.

611 The brain sections undergoing immunohistochemical staining were  
612 washed in PBS 3 times (10 minutes each time) and incubated in a blocking  
613 solution containing 0.3% TritonX-100 and 5% normal donkey serum (Jackson  
614 ImmunoResearch, USA) in PBS for 1 hour at 37°C. Sections were then  
615 incubated (4°C, 24 hours) with primary antibodies dissolved in 1% normal  
616 donkey serum solution. Afterward, sections were washed in PBS 4 times (15  
617 minutes each time), then incubated with secondary antibodies for 2 hours at  
618 room temperature. After DAPI staining and washing with PBS, sections were  
619 mounted on glass microscope slides, dried, and covered with 50% glycerin  
620 (ThermoFisher). The images were taken by the Leica DMI8 microscope and  
621 the Leica SP8 confocal microscopy. The images were further processed by Fiji  
622 and Photoshop.

### 623 **RNAscope in situ hybridization**

624 Mice were anesthetized with isoflurane and rapidly decapitated. Brains were  
625 roughly dissected from perfused mice and post-fixed in 4% PFA at 4 °C  
626 overnight, dehydrated in 30% sucrose 1×PBS at 4 °C for 2 days. Mouse brains

627 were embedded in OCT compound, cryosectioned in 15  $\mu$ m coronal slices,  
628 and mounted on SuperFrost Plus Gold slides (Fisher Scientific). In  
629 situ hybridization was performed according to the protocol of the RNAscope  
630 Multiplex Fluorescent Reagent Kit v2 (Cat. No. 320293). Probes were  
631 purchased from Advanced Cell Diagnostics: *c-Fos* (Cat. No. 316921-C2), *Tac1*  
632 (Cat. No. 410351-C2), *Tacr1* (Cat. No. 428781-C2), *Pdyn* (Cat. No. 318771),  
633 and *VgluT2* (Cat. No. 319171-C2). Primary antibodies include rabbit anti-c-Fos  
634 (Abcam, cat. No. ab190289, 1:4000), goat anti-CGRP (Abcam, ab36001,  
635 1:1000), and rabbit anti-DsRed (Clontech, Cat. No. 632496, 1:500). All  
636 secondary antibodies were purchased from Jackson ImmunoResearch and  
637 used at 1:400 dilution. Secondary antibodies include Alexa 488 donkey  
638 anti-rabbit (Cat. No. 711-545-152), Cy3 donkey anti-rabbit (Cat. No.  
639 711-165-152), and Alexa 488 donkey anti-goat (Cat. No. 705-546-147).  
640 Images were collected on a Leica fluorescence microscope and Leica LAS  
641 Software.

#### 642 **Fos induction**

643 The mice were habituated for three days and performed gentle grabbing and  
644 holding for 1 minute, five times every day to minimize background Fos  
645 expression.

646 To study the effect of pharmacogenetic manipulations on PVT-projecting  
647 PBN neurons, we intraperitoneally injected 0.5 mg/kg clozapine N-oxide (CNO,  
648 Sigma). Ninety minutes later, the brain tissues were processed. To assess  
649 2-MT evoked Fos expression in the PVT, the mice were kept in a chamber with  
650 a floor covered with cotton containing 100 ml, 1:1000 2-MT volatilized the  
651 predator odor for 90 minutes. To assess footshock-induced Fos expression in  
652 the PVT, we placed the mice into the chamber and delivered 30 times  
653 inevitable footshock (0.5 mA, 1 second) with a variable interval (averaging 60  
654 seconds). After stimulation, animals were kept in the same apparatus for  
655 another 60 minutes, and brain tissues were then processed.

656 For the dual Fos experiments, we first delivered 20 minutes 473 nm laser



657 pulses (20 Hz, 5 mW, 5ms) and left the mice to rest in the homecage for 60  
658 minutes. Then we delivered the 20 minutes footshock stimulus (0.5 mA, 1 s, 30  
659 times) and perfused the mice.

## 660 **Electrophysiology**

661 The electrophysiological experiment was performed as previously described  
662 (*Mu et al., 2017*). Mice were anesthetized with sevoflurane and perfused by  
663 the ice-cold solution containing (in mM) sucrose 213, KCl 2.5, NaH<sub>2</sub>PO<sub>4</sub> 1.25,  
664 MgSO<sub>4</sub> 10, CaCl<sub>2</sub> 0.5, NaHCO<sub>3</sub> 26, glucose 11 (300–305 mOsm). Brains were  
665 quickly dissected, and the coronal slice (250 μm) containing the PBN or PVT  
666 were chilled in ice-cold dissection buffer using a vibratome (V1200S, Leica) at  
667 a speed of 0.12 mm/second. The coronal sections were subsequently  
668 transferred to a chamber and incubated in the artificial cerebrospinal fluid  
669 (ACSF, 34°C) containing (in mM): NaCl 126, KCl 2.5, NaH<sub>2</sub>PO<sub>4</sub> 1.25, MgCl<sub>2</sub> 2,  
670 CaCl<sub>2</sub> 2, NaHCO<sub>3</sub> 26, glucose 10 (300–305 mOsm) to recover for at least 40  
671 minutes, then kept at room temperature before recording. All solutions were  
672 continuously bubbled with 95% O<sub>2</sub>/5% CO<sub>2</sub>.

673 All experiments were performed at near-physiological temperatures  
674 (30–32°C) using an in-line heater (Warner Instruments) while perfusing the  
675 recording chamber with ACSF at 3 ml/minute using a pump (HL-1, Shanghai  
676 Huxi). Whole-cell patch-clamp recordings were made from the target neurons  
677 under IR-DIC visualization and a CCD camera (Retiga ELECTRO, QIMAGING)  
678 using a fluorescent Olympus BX51WI microscope. Recording pipettes (2–5  
679 MΩ; Borosilicate Glass BF 150-86-10; Sutter Instrument) were prepared by a  
680 micropipette puller (P97; Sutter Instrument) and backfilled with  
681 potassium-based internal solution containing (in mM) K-gluconate 130, MgCl<sub>2</sub>  
682 1, CaCl<sub>2</sub> 1, KCl 1, HEPES 10, EGTA 11, Mg-ATP 2, Na-GTP 0.3 (pH 7.3, 290  
683 mOsm) or cesium-based internal solution contained (in mM) CsMeSO<sub>3</sub> 130,  
684 MgCl<sub>2</sub> 1, CaCl<sub>2</sub> 1, HEPES 10, QX-314 2, EGTA 11, Mg-ATP 2, Na-GTP 0.3 (pH  
685 7.3, 295 mOsm). Biocytin (0.2%) was included in the internal solution.

686 In PBN-PVT ChR2 experiments, whole-cell recordings of PBN neurons

687 with current-clamp ( $I = 0$  pA) were obtained with pipettes filled with the  
688 potassium-based internal solution. The 473 nm laser (5 Hz, 10 Hz, 20 Hz  
689 pulses, 0.5 ms duration,  $2 \text{ mW/mm}^2$ ) was used to activate PBN ChR2 positive  
690 neurons. Light-evoked EPSCs and IPSCs of PVT neurons recorded with  
691 voltage-clamp (holding voltage of -70 mV or 0 mV) were obtained with pipettes  
692 filled with the cesium-based internal solution. The 473 nm laser (20 Hz paired  
693 pulses, 1 ms duration,  $4 \text{ mW/mm}^2$ ) was used to activate ChR2 positive fibers.  
694 The light-evoked EPSCs were completely blocked by  $1 \mu\text{M}$  TTX (tetrodotoxin),  
695 rescued by  $100 \mu\text{M}$  4-AP (4-Aminopyridine), and blocked by  $10 \mu\text{M}$  NBQX  
696 (6-nitro-7-sulphamoylbenzo(f)quinoxaline-2,3-dione). NBQX and TTX were  
697 purchased from Tocris Bioscience. All other chemicals were obtained from  
698 Sigma.

699 Voltage-clamp and current-clamp recordings were carried out using a  
700 computer-controlled amplifier (MultiClamp 700B; Molecular Devices, USA).  
701 During recordings, traces were low-pass filtered at 4 kHz and digitized at 10  
702 kHz (DigiData 1550B1; Molecular Devices). Data were acquired by Clampex  
703 10.6 and filtered using a low-pass-Gaussian algorithm (-3 dB cut-off frequency  
704 = 1000 Hz) in Clampfit 10.6 (Molecular Devices).

#### 705 **Optogenetic manipulation**

706 For activating the PBN-PVT projection, a 473 nm laser (20 Hz, 5 ms pulse  
707 duration, 5 mW) was delivered. For inhibition of the PBN-PVT projection and  
708 the PVT-projecting PBN neurons, a constant laser (589 nm, 10 mW) was  
709 delivered.

#### 710 **Pharmacogenetic manipulation**

711 All behavioral tests were performed 30 minutes after intraperitoneal injection of  
712 0.5 mg/kg CNO in pharmacogenetic manipulation. Different behavior tests  
713 were performed at least three days apart.

#### 714 **Open field test**

715 The open field test (OFT) was used to assess locomotor activity and  
716 anxiety-related behavior in an open field arena (40 x 40 x 60 cm) with opaque

717 plexiglass walls. The mouse was placed in the center of the box and recorded  
718 by a camera attached to a computer. The movement was automatically  
719 tracked and analyzed by AniLab software (Ningbo AnLai, China). The total  
720 distance traveled, the total velocity, the total unmoving time (the mice were  
721 considered to be unmoving if unmoving time lasts more than 1 s), and time  
722 spent in the center area (20 x 20 cm) were measured. The box was cleaned  
723 with 70% ethanol after each trial.

724 To assess the effect of optogenetic activation of the PBN-PVT projection,  
725 15 minutes sessions consisting of 5 minutes pre-test (laser OFF), 5 minutes  
726 laser on test (laser ON), and 5 minutes post-test (laser OFF) periods. Laser  
727 (473 nm, 20 Hz, 5 ms, 5 mW) was delivered during the laser on phase.

728 To assess the effect of pharmacogenetic manipulations of PVT-projecting  
729 PBN neurons on locomotor activity and affective behaviors, we recorded the  
730 the movement 30 minutes after intraperitoneal (i.p.) injection with CNO.

731 To assess the effect of inhibition of the PBN-PVT projection on the  
732 aversive behaviors induced by 2-MT. One cotton ball containing 5 ml 2-MT  
733 (1:1000) solution was placed on the center of the upper left quadrant to  
734 disseminate fear-odor, then a constant laser (589 nm, 10 mW) was delivered  
735 during the 10 minutes test. The time spent in the 2-MT paired quadrant was  
736 calculated.

### 737 **Elevated zero maze (EZM)**

738 The EZM was an opaque plastic circle (60 cm diameter), which consisted of  
739 four sections with two opened and two closed quadrants. Each quadrant had a  
740 path width of 6 cm. The maze was elevated 50 cm above the floor. The  
741 animals were placed into an open section facing a closed quadrant and freely  
742 explored the maze for 5 minutes.

### 743 **Real-time place aversion (RTPA) test**

744 Mice were habituated to a custom-made 20 x 30 x 40 cm two-chamber  
745 apparatus (distinct wall colors and stripe patterns) before the test. Each mouse  
746 was placed in the center and allowed to explore both chambers without laser

747 stimulation for 10 minutes on Day 1. The movement was recorded for 10  
748 minutes as a baseline. The mice performed a slight preference for the black  
749 chamber according to the fact the mice have innate aversive to brightly  
750 illuminated areas. On Day 2, 473 nm laser stimulation (20 Hz, 5 ms, 5 mW)  
751 was automatically delivered when the mouse entered or stayed in the black  
752 chamber and turned off when the mouse exited the black chamber for 10  
753 minutes. Finally, the mouse was allowed to freely explore both chambers  
754 without laser stimulation for another 10 minutes. The RTPA location plots and  
755 total time on the stimulated side were recorded and counted with the AniLab  
756 software.

### 757 **Condition place aversion (CPA)**

758 After habituation, mice were placed in the center of the two-chamber  
759 apparatus and allowed to explore either chamber for 15 minutes on Day 1. On  
760 Day 2, mice were restricted to one chamber (laser paired chamber) with  
761 photostimulation (473 nm, 20 Hz, 5 ms, 5 mW) for 30 minutes in the morning  
762 and restricted to the other chamber (unpaired chamber) without  
763 photostimulation in the afternoon. On Day 3, mice were restricted to the  
764 unpaired chamber without photostimulation in the morning and restricted to the  
765 laser paired chamber with photostimulation in the afternoon. On Day 4, mice  
766 were allowed to explore both chambers without laser stimulation for another 15  
767 minutes. The time in the laser-paired chamber was calculated on Day 1 and  
768 Day 4.

### 769 **2-MT-induced aversion**

770 To assess the effect of optogenetic inhibition of the PBN-PVT projection or  
771 PVT-projecting PBN neurons on the aversive state, three cotton balls  
772 containing 15 ml 2-MT (1:1000) solution were placed in the black chamber. A  
773 constant laser (589 nm, 10 mW) was delivered during the 10 minutes test.

### 774 **Cue-dependent optogenetic conditioning test**

775 Video Freeze fear conditioning system with optogenetic equipment (MED  
776 Associates, MED-VFC-OPTO-USB-M) and Video Freeze software were used.

777 On Day 1, mice were habituated to the fear conditioning chambers and  
778 allowed to explore for 2 minutes freely, then three tones (75 dB, 4 kHz, 30  
779 seconds duration) separated by a variable interval with a range of 60–120  
780 seconds and the average of 90 seconds were delivered.

781 On Day 2, mice were trained with the sound cue (75 dB, 4 kHz, 30  
782 seconds) paired with a simultaneous 30 seconds laser pulse train (20 Hz, 5 ms,  
783 5 mW) for six times separated by a variable interval (averaging 90 seconds).  
784 The mice were kept in the conditioning chamber for another 60 seconds before  
785 returning to the home cages.

786 On Day 3, mice were placed back into the original training chamber for 3  
787 minutes to perform the contextual test. After 2–3 hours, the conditioning  
788 chamber was modified by changing its metal floor and sidewalls. Mice were  
789 placed in the altered chamber for 3 minutes to measure the freezing level in  
790 the altered context. A tone (75 dB, 4 kHz) was delivered for 30 seconds to  
791 perform the cue test.

792 The behavior of the mice was recorded and analyzed with the Video  
793 Freeze software. Freezing was defined as the complete absence of movement  
794 for at least 0.5 seconds. On the conditioning day, the freezing percentages  
795 were calculated for 30 seconds after each tone/laser stimulus. For the  
796 contextual test, the freezing percentages were calculated for three minutes.  
797 For the cue test, the freezing percentages were calculated for 30 seconds  
798 during tone.

### 799 **Auditory fear conditioning test**

800 On Day one, mice were habituated to the fear conditioning chambers. On Day  
801 two, mice were conditioned by seven trials of sound tone (75 dB, 4 kHz, 30 s)  
802 co-terminated with footshock (0.6 mA, 2 s) averagely separated by 90 seconds.  
803 Laser (589 nm, 10 mW) was delivered 1 second before the footshock and  
804 lasted for 4 seconds at each trial. On Day 3, mice were placed back into the  
805 original training chamber for 3 minutes to perform the contextual test, and the  
806 laser was delivered during the second minute. After 2–3 hours, the mice were

807 placed into a modified chamber to perform the cue test. Three tones were  
808 given averagely separated by 90 seconds. The laser was delivered during the  
809 second tone.

810 The behavior of the mice was recorded and analyzed with the Video  
811 Freeze software. The freezing percentages of the 27 seconds tone before  
812 laser (to avoid the influence of laser) for each trial were summarized to indicate  
813 fear memory acquisition in the conditioning test. For the contextual test, the  
814 freezing percentages were calculated for every minute. For the cue test, the  
815 freezing percentages were calculated for 30 seconds during tone.

### 816 **Freezing behavior**

817 For analyses of freezing behavior induced by pharmacogenetic activation  
818 of PVT-projecting PBN neurons, we injected CNO and recorded the mouse  
819 behavior using the Video Freeze fear conditioning system 30 minutes later.

820 The Video Freeze fear conditioning system (MED Associates,  
821 MED-VFC-OPTO-USB-M) was also used to assess the effect of optogenetic  
822 inhibition of PBN-PVT projection and the PVT-projecting PBN neurons on the  
823 fear-like behavior induced by footshock. After free exploration of the chamber  
824 for 2 minutes, 15 times footshocks (0.6 mA, 1 second) were delivered within 10  
825 minutes with a constant 589 nm laser (10 mW). The freezing percentages  
826 during 10 minutes were analyzed.

827 The Video Freeze fear conditioning system was also used to assess the  
828 effect of optogenetic inhibition of the PVT-projecting PBN neurons on the  
829 fear-like behavior induced by 2-MT. 10 ml 2-MT (1:1000) dissolved in the  
830 ddH<sub>2</sub>O was soaked into the cotton ball on the bottom of the training box. A  
831 constant laser (589 nm, 10 mW) was delivered during the tests.

### 832 **Tail suspension test (TST)**

833 Mice were individually suspended by an adhesive tape placed roughly 2 cm  
834 from the tip of the tail and videotaped for 6 minutes. Mice were considered  
835 immobile without initiated movements, and the immobility time was scored in  
836 the last 3 minutes by an observer unknown of the treatments.

837 **Forced swim test (FST)**

838 Mice were individually placed for 6 minutes in clear cylinders (45 cm height, 20  
839 cm internal diameter) containing freshwater (25°C, 15 cm depth). The  
840 swimming activity was videotaped, and immobility time in the last 3 minutes  
841 was counted manually by an investigator unaware of animal grouping. The  
842 mice were considered immobile when they stopped swimming/struggling or  
843 only slightly moved to keep the nose above the surface.

844 **von Frey test**

845 The von Frey test was used to assess the mechanical sensitivity (*Mu et al.,*  
846 *2017*). The mice were acclimated to the observation chambers for two days (2  
847 hours for each day) before the test. A series of von Frey hairs with  
848 logarithmically incrementing stiffness (0.16–2.0 grams) were used to stimulate  
849 the mouse hind paw perpendicularly. The 50% paw withdrawal threshold was  
850 determined using the up-down method.

851 **Hargreaves test**

852 Hargreaves tests were performed as described previously (*Mu et al., 2017*).  
853 Mice were placed in an individual plexiglass box with a glass floor. A radiant  
854 heat beam was exposed directly to the hind paw until the paw was withdrawn.  
855 The trials were repeated three times with an interval of at least 15 minutes. To  
856 avoid potential damage, the test was executed with a 20 seconds cut-off time.

857 **Formalin test**

858 In the formalin test, the mice received an intraplantar injection of formalin (5%,  
859 20 µl/mouse) and were placed into a plexiglass box (width: 10 cm, length: 10  
860 cm, height: 15 cm) individually to record the pain-related licking behaviors for 1  
861 hour. All videos were analyzed by trained investigators blinded to the  
862 experimental treatment of the animals.

863 **Rotarod test**

864 Mice were trained twice on a rotarod apparatus (MED Associates) with a rod  
865 accelerated 5–20 revolutions per minute (r.p.m.) for 5 minutes before the  
866 experimental day. On the second day, each mouse underwent three trials with



867 a rod was programmed to accelerate from 0 to 40 rpm over 300 seconds, then  
868 the average rpm at the point of falling was recorded.

### 869 **Fiber photometry**

870 *In vivo* fiber photometry experiments were performed as previously described  
871 (Zhu et al., 2020). After two weeks for virus expression, the mice were gently  
872 handled to be familiar with the calcium signal recording experiments  
873 (Thinker-Biotech). A signal (for synchronization) was manually tagged with the  
874 shock and air puff to evaluate the activity of PVT neurons. The calcium  
875 transient was recorded at 50 Hz. The fluorescence values change ( $\Delta F/F$ ) was  
876 calculated from the formula of  $(F-F_0)/F_0$  and the  $F_0$  represented the median  
877 of the fluorescence values in the baseline period (-1 to -0.5 seconds relative  
878 to the stimulation onset). To precisely quantify the change of the fluorescence  
879 values across the shock or air-puff stimulation, we defined 0.5 to 1.0 seconds  
880 after the onset as the post-stimulus period.

### 881 **Optoelectrode recording and analysis**

882 The homemade optoelectrode consisted of an optic fiber (200  $\mu$ m in diameter)  
883 glued to 16 individually insulated nichrome wires (35  $\mu$ m internal diameter,  
884 300-900 Kohm impedance, Stablohm 675, California Fine Wire). The 16  
885 microwire arrays were arranged in a 4 + 4 + 4 + 4 pattern and soldered to an  
886 18-pin connector (Mil-Max). Three weeks after virus injection, the  
887 optoelectrode was implanted to the PVT nucleus (AP -1.46 mm, ML 0 mm, DV  
888 -2.90 mm). After one week of recovery, two trials were performed continuously.  
889 Trial 1 contained ten sweeps of 2 s laser pulse trains (473 nm, 5 ms, 20 Hz, 8  
890 mW). The interval of sweeps was 60 s. Trial 2 contained twenty sweeps of 2 s  
891 footshock (0.5 mA). The interval of sweeps was 60 s. In the even time sweeps  
892 (2, 4, 6, 8, 10, 12, 14, 16, 18, 20), 2 s laser pulse trains were delivered  
893 spontaneously with the 2 s footshock. Neuronal signals were recorded using a  
894 Zeus system (Zeus, Bio-Signal Technologies: McKinney, TX, USA), and Spike  
895 signals were filtered online at 300 Hz. At the end of the experiment, all animals  
896 were perfused to confirm the optical fiber sites. Only the data of animals with

897 correct optical fiber sites and virus expression regions were analyzed.

898 The spikes were sorted by the valley-seeking method with Offline Sorter  
899 software (Plexon, USA) and analyzed with NeuroExplorer (Nex Technologies:  
900 Boston, MA, U.S.A.). Firing rates of the neurons and timestamps were  
901 exported for further analysis using customized scripts in MATLAB. The  
902 Kolmogorov-Smirnov (K-S) test was used to compare the spike firing rate of  
903 PVT during 2 s baseline (before stimulus) and 2 s after each stimulus.  $p <$   
904 0.001 indicated statistical significance. Z-score normalization maps were  
905 constructed from normalized firing rates.

### 906 **Quantification of the fiber intensity**

907 For quantification of fluorescence of PVT<sub>PBN</sub> efferents, the downstream targets  
908 of PVT<sub>PBN</sub> neurons were taken photofluorograms with identical exposure time,  
909 the mean fluorescence value in each ROI (400 x 400 pixels) of each brain  
910 region was analyzed by Fiji. The fiber intensity was calculated as the  
911 fluorescence value of each brain region divided by that of the NAc. All data  
912 came from at least three different mice and were presented as mean  $\pm$  SEM.

### 913 **Analysis**

914 Statistical detection methods include unpaired student's *t*-test, paired student's  
915 *t*-test, one-way ANOVA with Bonferroni's correction for multiple comparisons,  
916 two-way ANOVA with Bonferroni's correction for multiple comparisons. A value  
917 of  $p < 0.05$  was considered statistically significant. All data were represented  
918 as mean  $\pm$  SEM.

919

### 920 **REFERENCES**

921 Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. (2007). Evolving the  
922 lock to fit the key to create a family of G protein-coupled receptors potently  
923 activated by an inert ligand. *PNAS*, **104**:5163-5168. DOI:  
924 <https://doi.org/10.1073/pnas.0700293104>, PMID:17360345  
925 Barson JR, Mack NR, Gao WJ. The paraventricular nucleus of the thalamus is  
926 an important node in the emotional processing network. (2020). *Front Behav*

- 927 *Neurosci*, **14**:598469. DOI: 10.3389/fnbeh.2020.598469. PMID: 33192373
- 928 Beas BS, Wright BJ, Skirzewski M, Leng Y, Hyun JH, Koita O, Ringelberg N,  
929 Kwon HB, Buonanno A, Penzo MA. (2018). The locus coeruleus drives  
930 disinhibition in the midline thalamus via a dopaminergic mechanism. *Nature*  
931 *Neuroscience*, **21**:963-973. DOI: <https://doi.org/10.1038/s41593-018-0167-4>,  
932 PMID:29915192
- 933 Bowen AJ, Chen JY, Huang YW, Baertsch NA, Park S, Palmiter RD. (2020).  
934 Dissociable control of unconditioned responses and associative fear learning  
935 by parabrachial CGRP neurons. *eLife*, **9**. DOI:  
936 <https://doi.org/10.7554/eLife.59799>, PMID:32856589
- 937 Cai YQ, Wang W, Paulucci-Holthauzen A, Pan ZZ. (2018). Brain circuits  
938 mediating opposing effects on emotion and pain. *Journal of Neuroscience*,  
939 **38**:6340-6349. DOI: <https://doi.org/10.1523/JNEUROSCI.2780-17.2018>,  
940 PMID:29941444
- 941 Campos CA, Bowen AJ, Roman CW, Palmiter RD. (2018). Encoding of danger  
942 by parabrachial CGRP neurons. *Nature*, **555**:617-622. DOI:  
943 <https://doi.org/10.1038/nature25511>, PMID:29562230
- 944 Chen M, Bi LL. (2019). Optogenetic long-term depression induction in the  
945 PVT-CeL circuitry mediates decreased fear memory. *Mol Neurobiol*,  
946 **56**:4855-4865. DOI: 10.1007/s12035-018-1407-z. PMID: 30406427
- 947 Chiang MC, Bowen A, Schier LA, Tupone D, Uddin O, Heinricher MM. (2019).  
948 Parabrachial complex: a hub for pain and aversion. *Journal of Neuroscience*,  
949 **39**:8225-8230. DOI: <https://doi.org/10.1523/JNEUROSCI.1162-19.2019>,  
950 PMID:31619491
- 951 Chiang MC, Nguyen EK, Canto-Bustos M, Papale AE, Oswald AM, Ross SE.  
952 (2020). Divergent neural pathways emanating from the lateral parabrachial  
953 nucleus mediate distinct components of the pain response. *Neuron*,  
954 **106**:927-939. DOI: <https://doi.org/10.1016/j.neuron.2020.03.014>,  
955 PMID:32289251
- 956 Deng J, Zhou H, Lin JK, Wei YC, Xu XH, Sun YG. (2020). The parabrachial

957 nucleus directly channels spinal nociceptive signals to the intralaminar  
958 thalamic nuclei, but not the amygdala. *Neuron*, **107**:909-923. DOI:  
959 <https://doi.org/10.1016/j.neuron.2020.06.017>, PMID:32649865

960 Dimitrov EL, Tsuda MC, Cameron HA, Usdin TB. (2014). Anxiety- and  
961 depression-like behavior and impaired neurogenesis evoked by peripheral  
962 neuropathy persist following resolution of prolonged tactile hypersensitivity.  
963 *Journal of neuroscience*, **34**:12304-12312. DOI:  
964 <https://doi.org/10.1523/JNEUROSCI.0312-14.2014>, PMID:25209272

965 Do-Monte FH, Minier-Toribio A, Quiñones-Laracuenta K, Medina-Colón EM,  
966 Quirk GJ. (2017). Thalamic regulation of sucrose seeking during unexpected  
967 reward omission. *Neuron*, **94**:388-400. DOI: 10.1016/j.neuron.2017.03.036,  
968 PMID:28426970

969 Do-Monte FH, Quinones-Laracuenta K, Quirk GJ. (2015). A temporal shift in  
970 the circuits mediating retrieval of fear memory. *Nature*, **519**:460-463. DOI:  
971 <https://doi.org/10.1038/nature14030>, PMID:25600268

972 Engelke DS, Zhang XO, O'Malley JJ, Fernandez-Leon JA, Li S, Kirouac GJ,  
973 Beierlein M, Do-Monte FH.(2021). A hypothalamic-thalamostriatal circuit that  
974 controls approach-avoidance conflict in rats. *Nat Commun*, 12:2517. DOI:  
975 10.1038/s41467-021-22730-y. PMID: 33947849

976 Gao C, Leng Y, Ma J, Rooke V, Rodriguez-Gonzalez S, Ramakrishnan C,  
977 Deisseroth K, Penzo MA. (2020). Two genetically, anatomically and  
978 functionally distinct cell types segregate across anteroposterior axis of  
979 paraventricular thalamus. *Nat Neurosci*, **23**:217-228. DOI:  
980 10.1038/s41593-019-0572-3. PMID: 31932767

981 Han S, Soleiman MT, Soden ME, Zweifel LS, Palmiter RD. (2015). Elucidating  
982 an affective pain circuit that creates a threat memory. *Cell*, **162**:363-374. DOI:  
983 <https://doi.org/10.1016/j.cell.2015.05.057>, PMID:26186190

984 Hsu DT, Kirouac GJ, Zubieta JK, Bhatnagar S. (2014). Contributions of the  
985 paraventricular thalamic nucleus in the regulation of stress, motivation, and  
986 mood. *Frontiers in Behavioral Neuroscience*, **8**:73. DOI:

- 987 <https://doi.org/10.3389/fnbeh.2014.00073>, PMID:24653686
- 988 Huang TW, Lin SH, Malewicz NM, Zhang Y, Zhang Y, Goulding M, LaMotte RH,  
989 Ma QF. (2019). Identifying the pathways required for coping behaviours  
990 associated with sustained pain. *Nature*, **565**:86-90. DOI:  
991 <https://doi.org/10.1038/s41586-018-0793-8>, PMID:30532001
- 992 Isosaka T, Matsuo T, Yamaguchi T, Funabiki K, Nakanishi S, Kobayakawa R,  
993 Kobayakawa K. (2015). Htr2a-expressing cells in the central amygdala  
994 control the hierarchy between innate and learned fear. *Cell*, **163**:1153-1164.  
995 DOI: <https://doi.org/10.1016/j.cell.2015.10.047>, PMID:26590419
- 996 Jennings JH, Sparta DR, Stamatakis AM, Ung RL, Pleil KE, Kash TL, Stuber  
997 GD. (2013). Distinct extended amygdala circuits for divergent motivational  
998 states. *Nature*, **496**:224-228. DOI: <https://doi.org/10.1038/nature12041>,  
999 PMID:23515155
- 1000 Jimenez JC, Su K, Goldberg AR, Luna VM, Biane JS, Ordek G, Zhou P, Ong  
1001 SK, Wright MA, Zweifel L, Paninski L, Hen R, Kheirbek MA. (2018). Anxiety  
1002 cells in a hippocampal-hypothalamic circuit. *Neuron*, **97**:670-683. DOI:  
1003 <https://doi.org/10.1016/j.neuron.2018.01.016>, PMID:29397273
- 1004 Kaur S, Pedersen NP, Yokota S, Hur EE, Fuller PM, Lazarus M, Chamberlin  
1005 NL, Saper CB. (2013). Glutamatergic Signaling from the Parabrachial  
1006 Nucleus Plays a Critical Role in Hypercapnic Arousal. *Journal of*  
1007 *Neuroscience*, **33**:7627-7640. DOI:  
1008 <https://doi.org/10.1523/Jneurosci.0173-13.2013>,  
1009 PMID:WOS:000318420400003
- 1010 Keyes PC, Adams EL, Chen Z, Bi L, Nachtrab G, Wang VJ, Tessier-Lavigne M,  
1011 Zhu Y, Chen X. (2020). Orchestrating opiate-associated memories in  
1012 thalamic circuits. *Neuron*, **107**:1113-1123.e4. DOI:  
1013 [10.1016/j.neuron.2020.06.028](https://doi.org/10.1016/j.neuron.2020.06.028). PMID: 32679036
- 1014 Kirouac GJ. (2015). Placing the paraventricular nucleus of the thalamus within  
1015 the brain circuits that control behavior. *Neuroscience and Biobehavioral*  
1016 *Reviews*, **56**:315-329. DOI: <https://doi.org/10.1016/j.neubiorev.2015.08.005>,

- 1017 PMID:26255593
- 1018 Li S, Kirouac GJ. (2012). Sources of inputs to the anterior and posterior  
1019 aspects of the paraventricular nucleus of the thalamus. *Brain Structure &*  
1020 *Function*, **217**:257-273. DOI: <https://doi.org/10.1007/s00429-011-0360-7>,  
1021 PMID:22086160
- 1022 Liang SH, Yin JB, Sun Y, Bai Y, Zhou KX, Zhao WJ, Wang W, Dong YL, Li YQ.  
1023 (2016). Collateral projections from the lateral parabrachial nucleus to the  
1024 paraventricular thalamic nucleus and the central amygdaloid nucleus in the  
1025 rat. *Neuroscience Letters*, **629**:245-250. DOI:  
1026 <https://doi.org/10.1016/j.neulet.2016.07.017>, PMID:27423318
- 1027 Liang SH, Zhao WJ, Yin JB, Chen YB, Li JN, Feng B, Lu YC, Wang J, Dong YL,  
1028 Li YQ. (2020). A neural circuit from thalamic paraventricular nucleus to  
1029 central amygdala for the facilitation of neuropathic pain. *Journal of*  
1030 *Neuroscience*, **40**:7837-7854. DOI:  
1031 <https://doi.org/10.1523/JNEUROSCI.2487-19.2020>, PMID:32958568
- 1032 Mu D, Deng J, Liu KF, Wu ZY, Shi YF, Guo WM, Mao QQ, Liu XJ, Li H, Sun YG.  
1033 (2017). A central neural circuit for itch sensation. *Science*, **357**:695-699. DOI:  
1034 <https://doi.org/10.1126/science.aaf4918>, PMID:28818946
- 1035 Nakahara TS, Carvalho VMA, Souza MAA, Trintinalia GZ, Papes F. (2020).  
1036 Detection of activated mouse neurons with temporal resolution via dual c-Fos  
1037 staining. *STAR Protoc*, **1**:100153. DOI: [10.1016/j.xpro.2020.100153](https://doi.org/10.1016/j.xpro.2020.100153). PMID:  
1038 33377047
- 1039 Öhman A, Mineka S. (2001). Fears, phobias, and preparedness: Toward an  
1040 evolved module of fear and fear learning. *Psychological Review*, **108**:483-522.  
1041 DOI: <https://doi.org/10.1037/0033-295x.108.3.483>, PMID:11488376
- 1042 Palmiter RD. (2018). The parabrachial nucleus: CGRP neurons function as a  
1043 general alarm. *Trends in Neurosciences*, **41**:280-293. DOI:  
1044 <https://doi.org/10.1016/j.tins.2018.03.007>, PMID:29703377
- 1045 Penzo MA, Robert V, Tucciarone J, De Bundel D, Wang M, Van Aelst L,  
1046 Darvas M, Parada LF, Palmiter RD, He M, Huang ZJ, Li B. (2015). The

1047 paraventricular thalamus controls a central amygdala fear circuit. *Nature*,  
1048 **519**:455-459. DOI: <https://doi.org/10.1038/nature13978>, PMID:25600269

1049 Ren SC, Wang YL, Yue FG, Cheng XF, Dang RZ, Qiao QC, Sun XQ, Li X,  
1050 Jiang Q, Yao JW, Qin H, Wang GZ, Liao X, Gao D, Xia JX, Zhang J, Hu B,  
1051 Yan JA, Wang YJ, Xu M, et al. (2018). The paraventricular thalamus is a  
1052 critical thalamic area for wakefulness. *Science*, **362**:429-434. DOI:  
1053 <https://doi.org/10.1126/science.aat2512>, PMID:30361367

1054 Saper CB. (2016). The house alarm. *Cell Metabolism*, **23**:754-755. DOI:  
1055 <https://doi.org/10.1016/j.cmet.2016.04.021>, PMID:27166934

1056 Sun L, Liu R, Guo F, Wen MQ, Ma XL, Li KY, Sun H, Xu CL, Li YY, Wu MY, Zhu  
1057 ZG, Li XJ, Yu YQ, Chen Z, Li XY, Duan SM. (2020). Parabrachial nucleus  
1058 circuit governs neuropathic pain-like behavior. *Nature Communications*, **11**.  
1059 DOI: <https://doi.org/10.1038/s41467-020-19767-w>, PMID:33239627

1060 Todd AJ. (2010). Neuronal circuitry for pain processing in the dorsal horn.  
1061 *Nature Review Neuroscience*, **11**:823-836. DOI:  
1062 <https://doi.org/10.1038/nrn2947>, PMID:21068766

1063 Tye KM, Prakash R, Kim SY, Fenno LE, Grosenick L, Zarabi H, Thompson KR,  
1064 Gradinaru V, Ramakrishnan C, Deisseroth K. (2011). Amygdala circuitry  
1065 mediating reversible and bidirectional control of anxiety. *Nature*, **471**:358-362.  
1066 DOI: <https://doi.org/10.1038/nature09820>, PMID:21389985

1067 Vertes RP, Linley SB, Hoover WB. (2015). Limbic circuitry of the midline  
1068 thalamus. *Neuroscience and Biobehavioral Review*, **54**:89-107. DOI:  
1069 <https://doi.org/10.1016/j.neubiorev.2015.01.014>, PMID:25616182


1070 Yamamuro K, Bicks LK, Leventhal MB, Kato D, Im S, Flanigan ME, Garkun Y,  
1071 Norman KJ, Caro K, Sadahiro M, Kullander K, Akbarian S, Russo SJ,  
1072 Morishita H. (2020). A prefrontal-paraventricular thalamus circuit requires  
1073 juvenile social experience to regulate adult sociability in mice. *Nature*  
1074 *Neuroscience*, **23**:1240-1252. DOI:  
1075 <https://doi.org/10.1038/s41593-020-0695-6>, PMID:32868932

1076 Zhou WJ, Jin Y, Meng Q, Zhu X, Bai TJ, Tian YH, Mao Y, Wang LK, Xie W,



1077 Zhong N, Luo M, H., Tao WJ, Wang HT, Li J, Qiu BS, Zhou JN, Li XY, Xu H,  
1078 Wang K, Zhang XC, et al. (2019). A neural circuit for comorbid depressive  
1079 symptoms in chronic pain. *Nature Neuroscience*, **22**:1649-1658. DOI:  
1080 <https://doi.org/10.1038/s41593-019-0468-2>, PMID:31451801  
1081 Zhu YJ, Nachtrab G, Keyes PC, Allen WE, Luo LQ, Chen XK. (2018). Dynamic  
1082 salience processing in paraventricular thalamus gates associative learning.  
1083 *Science*, **362**:423-429. DOI: <https://doi.org/10.1126/science.aat0481>,  
1084 PMID:30361366  
1085 Zhu Y, Wienecke CF, Nachtrab G, Chen X. (2016). A thalamic input to the  
1086 nucleus accumbens mediates opiate dependence. *Nature*, **530**:219-222. DOI:  
1087 <https://doi.org/10.1038/nature16954>, PMID:26840481  
1088 Zhu YB, Xu L, Wang Y, Zhang Rui, Wang YC, Li JB, Mu D. (2020). Posterior  
1089 thalamic nucleus mediates facial histaminergic itch. *Neuroscience*, **444**:54-63.  
1090 DOI: <https://doi.org/10.1016/j.neuroscience.2020.07.048>, PMID:32750381  
1091 Zingg B, Chou XL, Zhang ZG, Mesik L, Liang F, Tao HW, Zhang LI. (2017).  
1092 AAV-Mediated anterograde transsynaptic tagging: mapping corticocollicular  
1093 input-defined neural pathways for defense behaviors. *Neuron*, **93**:33-47. DOI:  
1094 <https://doi.org/10.1016/j.neuron.2016.11.045>, PMID:27989459  
1095  
1096

1097 **Figures and figure legends**



1098

1099 **Figure 1.** Functional connectivity pattern of the PBN-PVT projection. (A) The  
 1100 schematic for virus injection of AAV2/8-hSyn-ChR2-mCherry into the PBN  
 1101 nucleus and the slice recording with 473 nm laser stimulation. (B) The  
 1102 projection fibers in the PVT nucleus. Scale bar: 100  $\mu$ m. (C) The  
 1103 AAV2/8-hSyn-ChR2-mCherry virus expression in the PBN nucleus. Scale bar:  
 1104 200  $\mu$ m. (D–F) The locations of the recorded cells in the anterior PVT (D), the  
 1105 middle PVT (E), and the posterior PVT (F). Red circles indicated neurons with  
 1106 excitatory postsynaptic currents (EPSCs), and blue circles indicated neurons  
 1107 without EPSCs. (G) The 473 nm laser-induced time-locked action potential  
 1108 firing at 5 Hz (top), 10 Hz (middle), and 20 Hz (bottom) in the ChR2-expressing  
 1109 neuron in the PBN. Scale bars: 100 ms, 40 mV. (H–J) The amplitude of  
 1110 light-evoked EPSCs (H), the latency of EPSCs (I), and the latency jitter of  
 1111 EPSCs (J) from all 34 responsive neurons in the PVT. (K) Amplitudes of  
 1112 light-evoked EPSCs recorded from a PVT neuron (right panel). (L) The

1113 light-evoked EPSC was completely blocked by 1  $\mu$ M tetrodotoxin (TTX),  
1114 rescued by 100  $\mu$ M 4-aminopyridine (4-AP), and blocked by 10  $\mu$ M NBQX  
1115 (AMPA/kainate receptor antagonist). Scale bars: 5 ms, 10 pA. (M) Schematic  
1116 shows retroAAV2/2-hSyn-Cre injection into the PVT nucleus on  
1117 *Rosa26-tdTomato* mice. (N) The injection site in the PVT nucleus. Scale bar:  
1118 200  $\mu$ m. (O and P) The distribution of the tdTomato positive neurons in the left  
1119 PBN (O) and the right PBN (P). (Q) The quantification of the tdTomato positive  
1120 neurons in the lateral PBN (LPBN) and the media PBN (MPBN).  $n = 4$  mice.  
1121 Scale bar: 200  $\mu$ m. (R–T) Double staining of tdTomato with *VgluT2* mRNA by in  
1122 situ hybridization. Scale bar: 50  $\mu$ m, the scale bar in the quadrangle was 25  
1123  $\mu$ m. (U) Quantification of the double-positive neurons over the total number of  
1124 tdTomato positive neurons,  $n = 6$  sections from 3 mice. \*\*\* $p < 0.001$ , data were  
1125 represented as mean  $\pm$  SEM. Paired student's *t*-test for Q.

1126


1127 The following figure supplement is available for figure 1:

1128 **Figure 1–figure supplement 1.** Characterization of PVT-projecting neurons in  
1129 the PBN nucleus.

1130 **Figure 1–figure supplement 2.** The distribution pattern of the PBN-PVT  
1131 glutamatergic projection.

1132 **Figure 1–figure supplement 3.** The distribution pattern of collateral projection  
1133 fibers from PVT-projecting PBN neurons.

1134



1135

1136 **Figure 2.** Optogenetic activation of the PBN-PVT projection induced negative  
 1137 affective states. (A) The illustration showed the injection of the  
 1138 AAV2/9-EF1a-DIO-ChR2-mCherry virus into the PBN nucleus and the optic  
 1139 fiber above the PVT on the *VgluT2-ires-Cre* mice. (B and C) The virus injection  
 1140 sites of the left PBN (B) and the right PBN (C). Scale bar: 200 μm. (D) The  
 1141 projection axons from the PBN and the location of the optic fiber (rectangle) in  
 1142 the PVT. Scale bar: 200 μm. (E) The schematic of the open field test (OFT)  
 1143 with optogenetic activation via a 473 nm laser. (F and G) The example traces  
 1144 of the 15 minutes optogenetic manipulation OFT from an  
 1145 AAV2/9-EF1a-DIO-mCherry virus injected mouse (F) or an  
 1146 AAV2/9-EF1a-DIO-ChR2-mCherry virus injected mouse (G). (H and I)  
 1147 Quantification of the velocity (H) and the center time (I) in the OFT, mCherry

1148 group:  $n = 7$  mice; ChR2 group:  $n = 8$  mice. (J) The illustration of the real-time  
1149 place aversion test (RTPA) with optogenetic activation via a 473 nm laser. The  
1150 right side was paired with the laser. (K and L) The example traces of the RTPA  
1151 and post-test from the mice injected with AAV2/9-EF1a-DIO-mCherry (K) or  
1152 AAV2/9-EF1a-DIO-ChR2-mCherry (L). (M) Quantification of the time spent in  
1153 the laser-paired chamber in the pre-test (Pre), RTPA, and post-test (Post),  
1154 mCherry group:  $n = 7$  mice; ChR2 group:  $n = 8$  mice. (N) Schematic timeline of  
1155 cue-dependent optogenetic conditioning. (O) Conditioned-freezing responses  
1156 to sound cue paired with optogenetic activation of the PBN-PVT projection  
1157 during training, mCherry group:  $n = 4$  mice; ChR2 group:  $n = 5$  mice. (P and Q)  
1158 Optogenetic activation of the projection fibers from the PBN in the PVT did not  
1159 induce context-dependent fear (P) and cue-dependent fear (Q), mCherry  
1160 group:  $n = 4$  mice; ChR2 group:  $n = 5$  mice. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ,  
1161 all data were represented as mean  $\pm$  SEM. Two-way ANOVA followed by  
1162 Bonferroni test for H, I, M, and O. Unpaired student's  $t$ -test for P and Q.

1163

1164 The following figure supplement is available for figure 2:

1165 **Figure 2–figure supplement 1.** The virus expression in the PBN and the optic  
1166 fiber position in the PVT of *VgluT2-ires-Cre* mice injected with  
1167 AAV2/9-EF1a-DIO-ChR2-mCherry virus or AAV2/9-EF1a-DIO-mCherry virus.


1168 **Figure 2–figure supplement 2.** Effects of optogenetic activation of PBN-PVT  
1169 projection in the OFT and the CPA.

1170 **Figure 2–video 1.** Optogenetic activation of PBN-PVT projection in OFT. The  
1171 473 nm laser (20 Hz, 5 ms, 5 mW) was delivered from 00:10 to 05:10 in the  
1172 video.

1173 **Figure 2–video 2.** Optogenetic activation of PBN-PVT projection in RTPA.  
1174 The 473 nm laser (20 Hz, 5 ms, 5 mW) was delivered when the mouse entered  
1175 the laser-paired chamber and withdrew when the mouse exited the  
1176 laser-paired chamber during the 10 minutes. The video was played with 4x  
1177 speed.



1178



1179

1180 **Figure 3.** Pharmacogenetic activation of the PVT-projecting PBN neurons  
 1181 induced anxiety-like behaviors and fear-like behaviors. (A) The illustration  
 1182 showed virus injection of retroAAV2/2-hSyn-Cre into the PVT nucleus and  
 1183 bilateral injection of AAV2/9-hSyn-DIO-hM3Dq-mCherry into the PBN nucleus.  
 1184 (B and C) CNO administration evokes Fos expression in  
 1185 AAV2/9-hSyn-DIO-hM3Dq-mCherry injected mice (B) but not in  
 1186 AAV2/9-EF1a-DIO-mCherry injected mice (C). Scale bar: 200  $\mu$ m. (D)  
 1187 Percentage of co-labeled neurons in the PBN, mCherry group:  $n = 3$  mice;  
 1188 hM3Dq group:  $n = 4$  mice. (E) The illustration of the OFT test with  
 1189 pharmacogenetic activation. (F) Example of the OFT traces from the mice  
 1190 infected with AAV2/9-EF1a-DIO-mCherry or  
 1191 AAV2/9-hSyn-DIO-hM3Dq-mCherry. (G–I) Quantification of the center time (G),  
 1192 the unmoving time (H), the total distance (I) in the OFT, mCherry group:  $n = 7$   
 1193 mice; hM3Dq group:  $n = 8$  mice. (J) Quantification of the velocity in the OFT,  
 1194 mCherry group:  $n = 7$  mice; hM3Dq group:  $n = 5$  mice. (K) Example elevated  
 1195 zero maze (EZM) traces from the mice infected with  
 1196 AAV2/9-EF1a-DIO-mCherry and AAV2/9-hSyn-DIO-hM3Dq-mCherry. (L)

1197 Quantification of the time spent in open quadrants in the EZM test,  $n = 8$  mice  
 1198 per group. (M) The illustration of pharmacogenetic activation-induced fear-like  
 1199 freezing behavior. (N) Pharmacogenetic activation of PVT-projecting PBN  
 1200 neurons induced fear-like freezing behaviors, mCherry group:  $n = 8$  mice;  
 1201 hM3Dq group:  $n = 7$  mice. \* $p < 0.05$ , \*\*\* $p < 0.001$ , all data were represented as  
 1202 mean  $\pm$  SEM. Unpaired student's  $t$ -test for D, G, H, I, and J. Two-way ANOVA  
 1203 followed by Bonferroni test for L and N.


1204

1205 The following figure supplements are available for figure 3:

1206 **Figure 3–figure supplement 1.** The virus expression in the PBN of mice  
 1207 injected with AAV2/9-hSyn-DIO-hM3Dq-mCherry or  
 1208 AAV2/9-EF1a-DIO-mCherry in the pharmacogenetic manipulation.

1209 **Figure 3–figure supplement 2.** Pharmacogenetic activation of PVT-projecting  
 1210 PBN neurons did not affect depressive-like behaviors, basal nociceptive  
 1211 thresholds, formalin-induced licking behavior, or motor function.

1212



1213

1214 **Figure 4.** Optogenetic inhibition of the PBN-PVT projection reduced



1215 aversion-like behavior and fear-like behaviors. (A) The illustration showed the  
1216 bilateral injection of AAV2/9-EF1a-DIO-NpHR3.0-EYFP virus into the PBN and  
1217 placement of optic fiber above the PVT on *VgluT2-ires-Cre* mice. (B and C)  
1218 Examples of AAV2/9-EF1a-DIO-NpHR3.0-EYFP expression in the PVT (B)  
1219 and PBN (C). The cyan rectangle represented the position of the optic fiber.  
1220 Scale bar: 200  $\mu$ m. (D) Schematic of 2-MT induced aversion test with  
1221 optogenetic inhibition via the 589 nm laser. (E) Representative traces of the  
1222 mice infected with AAV2/8-EF1a-DIO-EGFP or  
1223 AAV2/9-EF1a-DIO-NpHR3.0-EYFP in two chambers. (F and G) Quantification  
1224 of the time spent in the 2-MT paired chamber (F) and the total moving duration  
1225 (G),  $n = 7$  mice per group. \* $p < 0.05$ , \*\* $p < 0.01$ , (H) Representative traces of  
1226 the mice infected with AAV2/8-EF1a-DIO-EGFP or  
1227 AAV2/9-EF1a-DIO-NpHR3.0-EYFP in the OFT chamber. (I) Quantification of  
1228 the time spent in the 2-MT zone,  $n = 7$  mice per group. (J) Illustration of  
1229 footshock-induced freezing behavior with optogenetic inhibition via a 589 nm  
1230 laser. (K) Quantification of the freezing behavior,  $n = 7$  mice per group. \* $p <$   
1231 0.05, all data were represented as mean  $\pm$  SEM. Unpaired student's  $t$ -test for F,  
1232 G, I, and K.

1233


1234 The following figure supplements are available for figure 4:

1235 **Figure 4–figure supplement 1.** The virus expression in the PBN and the optic  
1236 fiber position in the PVT of *VgluT2-ires-Cre* mice injected with  
1237 AAV2/9-EF1a-DIO-NpHR3.0-EYFP or AAV2/8-EF1a-DIO-EGFP.

1238 **Figure 4–figure supplement 2.** Optogenetic inhibition of the PBN-PVT  
1239 projection did not affect associative fear memory acquisition and retrieval.

1240 **Figure 4–figure supplement 3.** Optogenetic inhibition of the PVT-projecting  
1241 PBN neurons reduced the aversion-like behavior and fear-like freezing  
1242 behavior.

1243



1244


1245 **Figure 5.** Activation of PVT<sub>PBN</sub> by diverse aversive stimuli. (A) The illustration  
1246 showed the injection of AAV2/1-hSyn-Cre into the PBN of *Rosa26-tdTomato*  
1247 mice. (B–D) The distribution of the neurons in the PVT at bregma -1.06 mm(B),  
1248 bregma -1.46 mm (C), and bregma -1.70 mm (D). Scale bar: 200  $\mu$ m. (E–G)  
1249 Fos induced by habituation control (E), footshock (F), or 2-MT (G) co-labeled  
1250 with the tdTomato positive neurons in the PVT. Scale bar: 200  $\mu$ m. (H)  
1251 Quantification of the co-labeled neurons,  $n = 3$  mice per group. \* $p < 0.05$ , \*\* $p <$   
1252  $0.01$ , \*\*\* $p < 0.001$ , all data were represented as mean  $\pm$  SEM, one-way  
1253 ANOVA followed by Bonferroni test for H.

1254

1255 The following figure supplements are available for figure 5:

1256 **Figure 5–figure supplement 1.** Calcium signals of PVT neurons in response  
1257 to aversive stimuli.

1258



1259


1260 **Figure 6.** Neuronal activity of the PVT neurons in response to the footshock  
 1261 was modulated by the PBN-PVT projection. (A) Top: Schematic showed  
 1262 injection of AAV2/9-EF1a-DIO-ChR2-mCherry into the PBN and placement of  
 1263 the optoelectrode above the PVT of *VgluT2-ires-Cre* mice. Bottom: The  
 1264 protocol of 10 sweeps of laser stimuli (Trial 1) and 20 sweeps of footshock  
 1265 stimuli without or with laser (Trial 2). (B) Firing rates (z-score) of 40 units  
 1266 during laser stimuli (20 Hz, 5 mW, 5 ms, 2 s). Inserted: percentages of different  
 1267 groups of neurons according to z-score. (C) Firing rates (z-score) of 40 units  
 1268 during footshock (0.5 mA, 2 s) without laser stimuli. (D) Percentage of  
 1269 laser-activated, footshock-activated, and both stimuli-activated units. (E-G)  
 1270 Rastergrams and firing rates showed the spiking activity of one PVT neuron  
 1271 during laser stimulus (E), footshock without laser stimulus (F), and footshock  
 1272 with laser stimulus (G). (H) Firing rates (z-score) of 40 units during footshock  
 1273 (0.5 mA, 2 s) with laser stimuli (20 Hz, 5 mW, 5 ms, 2 s). (I) Quantification of  
 1274 the firing rates of 40 units before and during footshock without and with laser,  $n$   
 1275 = 40 units. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , all data were represented as mean  $\pm$  SEM,  
 1276 two-way ANOVA followed by Bonferroni test for I.

1277

1278 The following figure supplements are available for figure 6:

1279 **Figure 6–figure supplement 1.** Dual Fos staining detecting Fos protein and  
 1280 *fos* mRNA induced by laser stimulation and footshock.

1281



1282

1283 **Figure 7.** Activation of PVT<sub>PBN</sub> neurons induced anxiety-like behaviors. (A)  
1284 The illustration showed injection of AAV2/1-hSyn-Cre into the PBN and  
1285 AAV2/9-hSyn-DIO-hM3Dq-mCherry into the PVT. (B and C) CNO  
1286 administration evoked Fos expression in AAV2/9-hSyn-DIO-hM3Dq-mCherry  
1287 injected mice (B) but not in AAV2/9-EF1a-DIO-mCherry injected mice (C).  
1288 Scale bar: 200  $\mu$ m. (D) Percentage of co-labeled neurons in the PVT,  $n = 4$   
1289 mice per group. (E) The illustration of the OFT test with pharmacogenetic  
1290 activation. (F) Quantification of center time in the OFT,  $n = 7$  mice per group.  
1291 (G) Example of elevated zero maze (EZM) traces from the mice injected with  
1292 AAV2/9-EF1a-DIO-mCherry or AAV2/9-hSyn-DIO-hM3Dq-mCherry. (H and I)  
1293 Quantification of the time spent in open quadrants (H) and the unmoving time  
1294 in the EZM test (I),  $n = 7$  mice per group. \* $p < 0.05$ , \*\*\* $p < 0.001$ , all data were  
1295 presented as mean  $\pm$  SEM. Unpaired student's  $t$ -test for D, F, H, and I.


1296

1297 The following figure supplements are available for figure 7:

1298 **Figure 7-figure supplement 1.** Distribution pattern of projection fibers of  
1299 PVT<sub>PBN</sub> neurons.

1300






1301

1302 **Figure 1–figure supplement 1.** Characterization of PVT-projecting neurons in  
1303 the PBN nucleus. (A–O) Double staining of tdTomato signals (red) with *Tacr1*  
1304 mRNA (A–C), *Tac1* mRNA (E–G), *Pdyn* mRNA (I–K), and CGRP protein  
1305 (M–O). Scale bar: 100  $\mu$ m. (D, H and L) The proportions of co-expressing  
1306 neurons of tdTomato positive neurons,  $n = 6$  sections from 3 mice. *Tacr1*,  
1307 tachykinin 1 receptor; *Tac1*, tachykinin 1; *Pdyn*, prodynorphin; CGRP,  
1308 calcitonin gene-related peptide.


1309



1310

1311 **Figure 1–figure supplement 2.** The distribution pattern of the PBN-PVT  
1312 glutamatergic projection. (A) The illustration for virus injection of  
1313 AAV2/8-EF1a-DIO-EGFP into the PBN nucleus on *VgluT2-ires-Cre* mice. (B–D)  
1314 The virus expression in the anterior (B), the middle (C), and the posterior PBN  
1315 (D). Scale bar: 200  $\mu$ m. (E–H) The distribution pattern of PBN glutamatergic  
1316 projection fibers in the anterior (E and F), the middle (G), and the posterior  
1317 PVT (H). PVA, anterior paraventricular thalamus. Scale bar: 200  $\mu$ m.

1318




1319

1320 **Figure 1–figure supplement 3.** The distribution pattern of collateral projection  
1321 fibers from PVT-projecting PBN neurons. (A) The illustration showed the  
1322 injection of retroAAV2/2-hSyn-Cre into the PVT and AAV2/8-EF1a-DIO-EGFP  
1323 into the PBN to label the PVT-projecting PBN neurons. (B) Examples of  
1324 AAV2/8-EF1a-DIO-EGFP expression in the PBN. Scale bar: 200  $\mu$ m. (C–N)  
1325 The efferents from the PVT-projecting PBN neurons could be found in the  
1326 MnPo (C), BNST (D), LH (E), PVN (F), PVT (G), ILN (H), DM (I), PSTh (J), VTA  
1327 (K) and PAG (L) but not in the CeA (M) and VMH (N). (O) Schematic showing  
1328 summary of the distribution pattern of fibers from PVT-projecting PBN neurons.  
1329 MnPo, Median preoptic nucleus; BNST, bed nucleus of the stria terminalis; LH,  
1330 lateral hypothalamic area; PVN, paraventricular nucleus of the hypothalamus;  
1331 ILN, intralaminar thalamic nucleus; DM, dorsomedial hypothalamic nucleus;



1332 PSTh, paraventricular thalamus; VTA, ventral tegmental areas; PAG,  
1333 periaqueductal gray; CeA, central nucleus of the amygdala; VMH,  
1334 ventromedial hypothalamic nucleus.


1335



1336

1337 **Figure 2–figure supplement 1.** The virus expression in the PBN and the optic  
1338 fiber position in the PVT of *VgluT2-ires-Cre* mice injected with  
1339 AAV2/9-EF1a-DIO-ChR2-mCherry virus or AAV2/9-EF1a-DIO-mCherry virus.  
1340 (A) Histological map showing area of ChR2 expression in the PBN at bregma  
1341  $-5.20$  mm in 8 mice. Scale bar:  $400\ \mu\text{m}$ . (B) The position of optic fiber  
1342 (rectangle) in the PVT in the AAV2/9-EF1a-DIO-ChR2-mCherry injected mice.  
1343 Scale bar:  $200\ \mu\text{m}$ . (C) The area of AAV2/9-EF1a-DIO-mCherry virus  
1344 expression in the PBN at bregma  $-5.20$  mm in 7 mice. Scale bar:  $400\ \mu\text{m}$ .


1345 Position of the optic fiber tip from 7 mice injected with  
1346 AAV2/9-EF1a-DIO-mCherry. Scale bar: 200  $\mu$ m.  
1347



1348

1349 **Figure 2–figure supplement 2.** Effects of optogenetic activation of PBN-PVT  
1350 projection fibers in the OFT and the CPA. (A and B) Quantification of the  
1351 unmoving time (A) and the distance (B) in the OFT (mCherry group:  $n = 7$  mice;  
1352 ChR2 group:  $n = 8$  mice). (C–F) Quantification of the velocity (C), the  
1353 unmoving time (D), the center time (E), the distance (F) and the number of  
1354 jumps (G) during the 5–10 minutes laser ON period in the OFT test (mCherry  
1355 group:  $n = 7$  mice; ChR2 group:  $n = 8$  mice). (H) Protocol for the prolonged  
1356 conditioned place aversion (CPA). (I) Photostimulation of PBN-PVT projection  
1357 did not induce CPA ( $n = 7$  mice per group). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ,  
1358 all data were represented as mean  $\pm$  SEM. Two-way ANOVA followed by  
1359 Bonferroni test for A, B, C, D, E, F, G, and I.

1360




1361

1362 **Figure 3–figure supplement 1.** The virus expression in the PBN of mice  
1363 injected with AAV2/9-hSyn-DIO-hM3Dq-mCherry or  
1364 AAV2/9-EF1a-DIO-mCherry in the pharmacogenetic manipulation. (A)  
1365 Representative histological images of hM3Dq expression in an  
1366 AAV2/9-hSyn-DIO-hM3Dq-mCherry injected mouse at brain level from bregma  
1367 –5.02 mm to bregma –5.34 mm. Scale bar: 1 mm. (B) Depiction of virus




1368 infection area according to the histological images in (A). (C) Superimposed  
1369 depiction of virus transduction from 8 mice. (D) Representative histological  
1370 images of mCherry expression in an AAV2/9-EF1a-DIO-mCherry injected mice  
1371 at brain level from bregma  $-5.02$  mm to bregma  $-5.34$  mm. Scale bar: 1 mm.  
1372 (E) Depiction of virus infection area according to the histological images in (D).  
1373 (F) Superimposed depiction of virus transduction from 8 mice.  
1374



1375  
1376 **Figure 3–figure supplement 2.** Pharmacogenetic activation of PVT-projecting  
1377 PBN neurons did not affect depressive-like behaviors, basal nociceptive  
1378 thresholds, formalin-induced licking behavior, or motor function. (A) Immobility  
1379 time in the tail suspension test (TST),  $n = 7$  mice per group. (B) Immobility time  
1380 in the forced swimming test (FST), mCherry group:  $n = 7$  mice; hM3Dq group:  
1381  $n = 8$  mice. (C and D) Effects of pharmacogenetic activation of PVT-projecting  
1382 PBN neurons on the nociceptive response tested by von Frey (C) and  
1383 Hargreaves (D),  $n = 8$  mice per group. (E and F) Duration of licking behaviors  
1384 in the formalin-induced inflammatory pain test, mCherry group:  $n = 7$  mice;  
1385 hM3Dq group:  $n = 8$  mice. Phase I: 0–10 minutes, Phase II: 10–60 minutes. (G)  
1386 The latency to fall in the rotarod test,  $n = 8$  mice per group. Data were  
1387 represented as mean  $\pm$  SEM. Unpaired student's  $t$ -test for A, B and G.  
1388 Two-way ANOVA followed by Bonferroni test for C, D, E, and F.  
1389


1390



1391

1392 **Figure 4–figure supplement 1.** The virus expression in the PBN and the optic  
1393 fiber position in the PVT of *VgluT2-ires-Cre* mice injected with  
1394 AAV2/9-EF1a-DIO-NpHR3.0-EYFP or AAV2/8-EF1a-DIO-EGFP. (A)  
1395 Histological map showing area of NpHR3.0 expression in the PBN at bregma  
1396 –5.20 mm in 7 mice. Scale bar: 400  $\mu$ m. (B) The position of optic fiber  
1397 (rectangle) in the PVT in the AAV2/9-EF1a-DIO-NpHR3.0-EYFP injected mice.  
1398 Scale bar: 200  $\mu$ m. (C) The area of AAV2/8-EF1a-DIO-EGFP expression in the  
1399 PBN at bregma –5.20 mm in 7 mice. Scale bar: 400  $\mu$ m. (D) Position of the  
1400 optic fiber tip from 7 mice injected with AAV2/9-EF1a-DIO-mCherry. Scale bar:  
1401 200  $\mu$ m.


1402



1403

1404 **Figure 4-figure supplement 2.** Optogenetic inhibition of the PBN-PVT  
1405 projection did not affect associative fear memory acquisition and retrieval. (A)  
1406 The protocol of auditory fear conditioning experiments with optogenetic  
1407 inhibition of the PBN-PVT projection. (B–D) Quantification of freezing levels  
1408 during condition trials (B), contextual test (C), and cue test (D),  $n = 7$  mice per  
1409 group. The yellow box indicated optogenetic inhibition. All data were  
1410 represented as mean  $\pm$  SEM, two-way ANOVA followed by Bonferroni test for  
1411 B, C and D.

1412



1413

1414 **Figure 4-figure supplement 3.** Optogenetic inhibition of the PVT-projecting

1415 PBN neurons reduced the aversion-like behavior and fear-like freezing

1416 behavior. (A) The illustration showed virus injection of retroAAV2/2-hSyn-Cre

1417 into the PVT, bilateral injection of AAV2/9-EF1a-DIO-NpHR3.0-EYFP into the

1418 PBN, and bilateral placement of optic fiber above the PBN on WT mice. (B and

1419 C) Examples of AAV2/9-EF1a-DIO-NpHR3.0-EYFP (B) and

1420 AAV2/8-EF1a-DIO-EGFP (C) expression in the PBN, the rectangle

1421 represented the position of the optic fiber. Scale bar: 200  $\mu$ m. (D) Schematic of

1422 2-MT induced aversion test with optogenetic inhibition via a 589 nm laser. (E)

1423 Representative traces of the mice infected with AAV2/8-EF1a-DIO-EGFP or

1424 AAV2/9-EF1a-DIO-NpHR3.0-EYFP in the chamber. (F and G) Quantification of

1425 the time spent in the 2-MT paired chamber (F) and the moving duration (G),  $n$

1426 = 5 mice per group. (H) Schematic of 2-MT induced fear-like freezing behavior

1427 with optogenetic inhibition via a 589 nm laser. (I) Quantification of the freezing

1428 behavior,  $n$  = 5 mice per group. (J) Illustration of footshock-induced freezing


1429 behavior with optogenetic inhibition via a 589 nm laser. (K) Quantification of

1430 the freezing behavior,  $n$  = 5 mice per group. \* $p$  < 0.05, \*\* $p$  < 0.01, all data were



1431 represented as mean  $\pm$  SEM. Unpaired student's *t*-test for F, G, I, and K.

1432



1433

1434 **Figure 5–figure supplement 1.** Calcium signals of PVT neurons in response

1435 to aversive stimuli. (A) Schematic showed injection of AAV2/8-hSyn-GCaMP6s

1436 into the PVT and placement of the optic fiber above the PVT. (B)

1437 Representative of GCaMP6s expression and the position of optic fiber in the

1438 PVT. Scale bar: 400  $\mu$ m. (C and D) The calcium signal of the PVT neurons (C)

1439 and the quantification of the average  $Ca^{2+}$  signal before and after footshock

1440 (D). The black bar represented the baseline period (B.s, -1 to -0.5 s), and the


1441 red bar represented the post-stimulus period (Post, 0.5 to 1 s),  $n = 5$  mice. (E

1442 and F) The calcium signal of the PVT neurons (E) and the quantification of

1443 average  $Ca^{2+}$  signal before and after air puff (F),  $n = 5$  mice. \*\* $p < 0.01$ , all data

1444 were represented as mean  $\pm$  SEM. Paired student's *t*-test for D and F.

1445



1446

1447 **Figure 6–figure supplement 1.** Dual Fos staining detecting Fos protein and

1448 *fos* mRNA induced by laser stimulation and footshock. (A) Top: Schematic


1449 showed injection of AAV2/9-EF1a-DIO-ChR2-mCherry into the PBN and

1450 placement of the optic fiber above the PVT of *VgluT2-ires-Cre* mice. Bottom:

1451 Time windows containing laser (20 Hz, 5 mW, 5ms) and shock stimuli (0.5 mA,

1452 1 s, 30 times), separated by 60 minutes of the rest period. (B–D) Example of

1453 Fos protein and *fos* mRNA expression in the PVT. Red fluorescence  
1454 represents Fos protein induced by laser stimulus, and green fluorescence  
1455 indicates *fos* mRNA detected by *in situ* hybridizations. Scale bar: 100  $\mu$ m. (E)  
1456 The proportion of co-expression neurons over Fos protein-expressing cells  
1457 and *fos* mRNA-expressing cells,  $n = 5$  mice.  
1458



1459  
1460 **Figure 7-figure supplement 1.** Distribution pattern of projection fibers of  
1461 PVT<sub>PBN</sub> neurons. (A) The illustration showed injection of AAV2/1-hSyn-Cre into  
1462 the PBN and AAV2/8-EF1a-DIO-EGFP into the PVT of *Rosa26-tdTomato* mice.  
1463 (B) The representative image of EGFP and tdTomato-transduced neurons in  
1464 the PVT. Scale bar: 200  $\mu$ m. (C–G) Distribution patterns of EGFP fibers in the  
1465 PFC (C), CI (D), NAc (E), BNST (F), and CeA (G). PFC, prefrontal cortex; IC,  
1466 insular cortex; CI, claustrum; NAc, nucleus accumbens core; BNST, bed  
1467 nucleus of the stria terminalis; CeA, central nucleus of the amygdala. Scale bar:  
1468 200  $\mu$ m. (H) Quantification of the fiber intensity in these brain regions,  $n = 3$   
1469 mice.